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A B S T R A C T   
The adult human adrenal cortex produces steroid hormones that are crucial for life, supporting immune response, 
glucose homeostasis, salt balance and sexual maturation. It consists of three histologically distinct and func-
tionally specialized zones. The fetal adrenal forms from mesodermal material and produces predominantly ad-
renal C19 steroids from its fetal zone, which involutes after birth. Transition to the adult cortex occurs 
immediately after birth for the formation of the zona glomerulosa and fasciculata for aldosterone and cortisol 
production and continues through infancy until the zona reticularis for adrenal androgen production is formed 
with adrenarche. The development of this indispensable organ is complex and not fully understood. This article 
gives an overview of recent knowledge gained of adrenal biology from two perspectives: one, from basic science 
studying adrenal development, zonation and homeostasis; and two, from adrenal disorders identified in persons 
manifesting with various isolated or syndromic forms of primary adrenal insufficiency.   
1. Introduction 
Adrenal glands are key endocrine organs that participate in the 
hormonal regulation of vital aspects of human life, including stress and 
immune response, sexual maturation and salt balance. They are 
composed of two tissues with distinct function and developmental 
origin. The adrenal cortex produces steroids and descends from pre-
cursors of the coelomic epithelium (mesoderm); while the inner me-
dulla, surrounded by the cortex, contains chromaffin cells that secrete 
catecholamines and originate from cells of the fetal neural crest (ecto-
derm). This article will focus on the adrenal cortex. 
The first part of this review article discusses the recent advancements 
in adrenal investigations that study adrenocortical structure, develop-
ment and homeostasis. This field has seen notable breakthroughs within 
the past 15 years and has led to important results on how cell dynamics, 
tissue structure and steroidogenic function are interconnected. Relevant 
implications of these studies include the possibility of reprogramming 
pluripotent cells to tunable steroid-producing cells as a therapeutic 
approach to compensate for missing steroid function that may lead to 
opportunities to cure disorders of adrenal insufficiency tomorrow. 
The second part of this review article will focus on the steroidogenic 
function of the adrenal cortex. This aspect of adrenal physiology has 
been thoroughly investigated since the first description of clinical cases 
of adrenal insufficiency by Thomas Addison (1856). This report was 
followed by several efforts in isolating adrenal extract and single cortical 
steroids (known today as ‘corticosteroids’) with the therapeutic inten-
tion of replacing missing steroids in affected patients. These studies have 
all contributed towards the current comprehensive knowledge of the 
biochemical and genetic characteristics of the pathways of adrenal ste-
roidogenesis. By contrast, the therapeutic approach to adrenal insuffi-
ciency in patients has seen little improvement over the last years, with 
life-long steroid replacement therapy remaining the only treatment 
available so far. The primary role of steroids for the quality of life, as 
well as the urgent need for better solutions to adrenal insufficiency 
syndromes are underscored by the severe pathological effects of steroid 
deficiency, ranging from mild manifestations like low blood pressure 
and chronic fatigue to life-threatening salt-wasting adrenal crises that 
may result in sudden death due to Addison’s crisis. Therefore, still today, 
patients with adrenal insufficiency do have a reduced life expectancy 
(Hummel et al., 2016). 
The third part of this article summarizes human adrenal disorders 
resulting from disruption of steroidogenesis and/or adrenal develop-
ment, homeostasis and structure. In particular, we discuss selected 
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monogenic disorders of adrenal insufficiency caused by congenital ad-
renal hypoplasia, hyperplasia and other syndromic and non-syndromic 
disorders affecting adrenal function. 
Finally, in the last part of this update, we report on novel models 
used for adrenal research and their opportunities and challenges to 
enhance the knowledge of the biology of the adrenal cortex forward. 
Overall, this article highlights critical aspects of adrenal cortex 
development, homeostasis, function and disease, with a focus on novel 
aspects that have emerged in the past decade. It does not claim to be 
comprehensive but will refer to such reviews whenever possible. The 
reader will notice that substantial amount of data collected so far about 
adrenocortical structure and development originates from animal 
studies (mostly mouse models) (Table 1), while data on steroid 
biochemistry and disorders originate from “human experiments of na-
ture” (Table 2). The authors indicate therefore throughout the text 
whether described data derive from animal or human studies, to help the 
reader discriminate between the two. In fact, although animal studies 
have traditionally informed on key human adrenal mechanisms (e.g. the 
role of Steroidogenic Factor 1 (SF-1) in development and function of 
adult steroidogenic organs, including the adrenal), the transferability of 
most animal findings to human physiology has yet to be experimentally 
tested. Notable discrepancies between rodent and human physiology are 
evident. For instance, in adrenal zonal organization of most animals a 
region resembling the human zona Reticularis (zR) is missing and with it 
the developmental event of adrenarche. Species-specific expression of 
CYP17A1 coding for 17α-hydroxylase/17–20 lyase activity enables the 
human, but not the mouse adrenals to produce cortisol and adrenal 
androgens. Besides, adrenal development in human features the devel-
opment of a functional transitory ‘fetal zone’ or ‘fetal cortex’ (FZ), which 
is absent in the mouse. These discrepancies then translate into remark-
able differences in the clinical outcome of monogenic variants, whereby 
genes implicated in human adrenal pathologies may not result in a 
similar phenotype when inactivated in mice, or vice versa. Therefore, 
readers are invited to use caution in the interpretation of results of ad-
renal studies, especially if they are interested in a comprehensive, all- 
including view of the adrenal physiology in human, which still poses 
many unanswered questions. 
2. Adrenocortical structure, development and homeostasis 
The adrenal cortex is a highly dynamic, vital steroidogenic hub, 
implicated in the control of many homeostatic functions mediated by 
three types of steroid hormones: mineralocorticoids, glucocorticoids and 
adrenal androgens. Steroid production is compartmentalized in as many 
epithelial concentric layers, referred to as ‘zones’, thanks to the segre-
gation of specific enzymes and cofactors. The subdivision of the adrenal 
cortex in distinct functional zones is conventionally referred to as 
‘functional zonation’. Teleologically, functional zonation allows discrete 
regulation of each steroid type, and consequent independent control of 
each steroid function. The adrenal cortex is surrounded by a 
Abbreviations 
DZ ‘definitive zone’ or ‘definitive cortex’ 
FZ ‘fetal zone’ or ‘fetal cortex’ 
CYP11B1 11β-hydroxylase 
HSD17B6 17β hydroxysteroid dehydrogenase 6 
CYP21A2 21-hydroxylase 
HSD3B2 3β-hydroxysteroid dehydrogenase 
SRD5A1 5α-reductase 
ATP adenosine triphosphate 
AHC Adrenal hypoplasia congenita 
ACTH Adrenocorticotropin Hormone 
FDXR Adrenodoxin Reductase 
AGP adrenogonadal primordium 
AKR1C2 Aldo-keto reductase family 1 member C2 
AKR1C4 Aldo-keto reductase family 1 member C4 
AS Aldosterone Synthase 
CREM AMP-responsive element modulator 
ABS Antley Bixler syndrome 
CaMKs Calcium/calmodulin-dependent protein Kinases 
PRKAR1A cAMP-dependent protein kinase type I-alpha regulatory 
subunit 
CREB cAMP-responsive element binding protein 
CITED2 Cbp/p300-interacting transactivator 2 
CAH congenital adrenal hyperplasia 
CRH corticotropin releasing hormone 
cAMP Cyclic Adenosine Monophosphate 
POR Cytochrome P450 Reductase 
dpc days post conception 
DadE Definitive adrenal-specific enhancer 
DAB2 Disabled homolog 2 
DMD Duchenne muscular dystrophy 
E embryonic day 
FGD Familial glucocorticoid deficiency 
FAdE fetal adrenal-specific enhancer 
GPX1 glutathione peroxidase 1 
GKD glycerol kinase deficiency 
Gaq Guanine nucleotide-binding protein G(q) subunit alpha 
HOX homeobox proteins 
hiSCs human induced steroidogenic cells 
LGR Leucine-rich repeat-containing G-protein coupled Receptor 
MCM4 minichromosome maintenance 4 
NADPH Nicotinamide Adenine Dinucleotide Phosphate 
NNT Nicotinamide Nucleotide Transhydrogenase 
NPC Niemann Pick type C 
DAX1 nuclear repressor protein dosage-sensitive sex reversal, 
adrenal hypoplasia critical region, on chromosome X, gene 
1 
OMIM Online Mendelian Inheritance in Man 
OTC ornithine transcarbamylase 
PTCH1 Patched 1 
PRDX3 peroxiredoxin 3 
PBX1 pre–B-cell leukemia transcription factor 1 
PAI primary adrenal insufficiency 
PPNAD primary pigmented nodular adrenocortical disease 
PCNA proliferating cell nuclear antigen 
PKA Protein Kinase A 
ROS reactive oxygen species 
RAAS Renin-Angiotensin-Aldosterone system 
RSPOs R-spondins 
SHH Sonic Hedgehog 
S1P sphingosine-1-phosphate 
SGPL1 sphingosine-1-phosphate lyase 1 
StAR Steroidogenic Acute Regulatory protein 
SF-1 Steroidogenic Factor 1 
TXNRD2 thioredoxin reductase 2 
HPA this hypothalamic-pituitary-adrenal 
AAAS triple A syndrome 
WT1 Wilms’ tumor protein 1 
WIF Wnt inhibitory factor 
zF zona Fasciculata 
zG zona Glomerulosa 
zR zona Reticularis  
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mesenchymal capsule, which is composed of a layer of elongated, 
fibroblast-like cells and fibrous tissue that supports the cortex by 
providing structural containment and critical signaling information for 
the development, adult maintenance and regeneration of the gland. 
2.1. Distinct histological characteristics and functions of the cortical zones 
The first report that describes the subdivision of the adrenocortical 
zones came in the second half of the nineteenth century, with the 
observation by Julius Arnold that the human and bovine adrenal cortex 
Table 1 
Selected genes involved in adrenal development, zonation and homeostasis. Lessons learned from mouse developmental biology and their suggested human correlate 




Phenotype associated with gene inactivation in mouse Human 
gene name 
OMIM Human disorder 
Axin2 Accelerated ossification leading to premature fusion of cranial 
structures (Yu, 2005) 
AXIN2 114500 608615 Oligodontia-colorectal cancer syndrome 
Cited2 Embryonic lethality associated with cardiac malformations, 
adrenal agenesis, abnormal cranial ganglia, exencephaly, liver 
dysgenesis, XY sex reversal, eye, lung and placental defects. 
Conditional inactivation show failure in maintenance of adult 
hematopoietic stem cells (Bamforth et al., 2001; Buaas et al., 
2009; Chen et al., 2008; Kranc et al., 2009; Qu et al., 2007; Val 
et al., 2007; Weninger et al., 2005; Withington et al., 2006; Xu 
et al., 2008). 
CITED2 614431 614433 Atrioventricular septal defects 
Ezh2 Lethality before gastrulation. Conditional inactivation results in 
primary glucocorticoids insufficiency and aberrant zonal 
differentiation (Mathieu et al., 2018; Shen et al., 2008) 
EZH2 277590 Weaver syndrome 
Gata4 Defects of cardiac and pancreatic development, impaired male 
and female gonadal function (Carrasco et al., 2012; Kyrönlahti 
et al., 2011a, 2011b; Tevosian et al., 2015) 
GATA4 615542 607941 614430 
187500 614429 
Testicular and cardiac anomalies, including 
atrioventricular septal defects 
Gata6 Eary death at implantation, associated with extraembryonic tissue 
defects. Conditional inactivation results in adrenal hypoplasia ( 
Koutsourakis et al., 1999; Tevosian et al., 2015) 
GATA6 614475 614474 600001 
217095 187500 
Cardiac defects included in the Tetralogy of Fallot, 
pandreatic agenesis 
Gli1 No evident phenotype (Park et al., 2000) GLI1 618123 174400 Polydactyly 
Hoxb5 Variable anteriorizing homeotic vertrebrae transformations and 
rostral shift of the shoulder girdle (Rancourt et al., 1995) 
HOXB5 - - 
Hoxb9 Developmental defects in thoracic skeletal elements (Chen and 
Capecchi, 1997) 
HOXB9 - - 
Lef1 Growth retardation and postnatally lethality associated with 
defective developent of multiple organs, including mammary 
glands, vasculature and body hair (van Genderen et al., 1994) 
LEF1 - Somatic sebaceous tumors. 
Nr0b1 Abnormal reproductive development in the hemizygote, ranging 
from defects in testes development and spermatogenesis to 
complete male to female sex reversal, progressive adrenal failure ( 
Scheys et al., 2011; Yu et al., 1998) 
NR0B1 300018 300200 Congenital adrenal hypoplasia. 
Nr5a1 Agenesis of adrenal glands and gonads, defects of the 
ventromedial hypothalamic nucleus and pituitary gonadotrophs, 
neonatal lethality (Beuschlein et al., 2002) 
NR5A1 612964 613957612964 
612965 617480 
Haploinsufficiency leads to andrenocortical 
insufficiency, ovarian and spermatogenic failure, 
46, XX sex reversal. 
Pbx1 Late gestational death, hypoplasia or aplasia of multiple organs, 
impaired hematopoiesis, skin edema, axial and appendicular 
skeleton defects, absent adrenal glands, impared developent of 
bone, kidney and pancreas (DiMartino et al., 2001; Kim et al., 
2002; Schnabel et al., 2003a, 2003b; Selleri et al., 2001) 
PBX1 617641 Congenital anomalies of kidney and urinary tract 
syndrome with or without hearing loss, abnormal 
ears, or developmental delay. 
Prkar1a Embryonic lethality during organogenesis due to multiple 
developmental patterning defects (Amieux et al., 2002) 
PRKAR1A 101800 160980 255960 
610489 
Carney complex, pigmented nodular adrenocortical 
disease (PPNAD). 
Rnf43 Hyperproliferation of intestinal and stomach epithelium ( 
Neumeyer et al., 2019) 
RNF43 617108 Sessile serrated polyposis cancer syndrome. 
Rspo3 Lethality during organogenesis due to impaired placenta 
formation. Conditional inactivation results in imparied adrenal 
development and loss of cell replenishment in the adult adrenal ( 
Aoki et al., 2007; Vidal et al., 2016) 
RSPO3   
Shh Mid-gestation death associated with impaired development of 
limbs, eyes, ears, external genitalia and mouth (Chiang et al., 
1996) 
SHH 142945 611638 269160 
147250 
Holoprosencephaly, microphthalmia with 
coloboma, schizencephaly, single median maxillary 
central incisor. 
Tcf21 Lethality around birth due to hypoplastic lungs and kidneys, with 
abnormal vasculature of these organs and the hemopericardium. 
Asplenia only in one mouse model (Lu et al., 2000; Quaggin et al., 
1999) 
TCF21 - - 
Wnt4 Perinatal lethality associated with impaired development of the 
kidney, lung and pituitary gland and female reproductive system. 
Conditional inactivation results in impaired zG differentiation. ( 
Caprioli et al., 2015; Drelon et al., 2016; Heikkilä et al., 2002;  
Stark et al., 1994; Treier et al., 1998; Vainio et al., 1999) 
WNT4 611812 158330 SERKAL syndrome, Müllerian aplasia and 
hyperandrogenism. 
Wt1 Late gestational death, impaired renal, gonadal, adrenal, splenic, 
pulmonar, cardiac and mesothelial development (Bandiera et al., 
2013; Kreidberg et al., 1993) 
WT1 194080 136680 608978 
156240 256370 194070 
Denys-Drash syndrome, Frasier syndrome, 
Meacham syndrome, mesothelioma, nephrotic 
syndrome and Wilms tumor. 
Znrf3 Lethality around birth associated with abnormal lens 
development. Conditional inactivation results in adrenal 
hyperplasia (Hao et al., 2012, 2012, 2012) 
ZNRF3 - -  
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are subdivided into three distinct topological and morphological regions 
(Dostoiewsky, 1886). Later studies built on this report by indicating that 
each zone secretes unique types of steroids, and highlighted a strong 
correlation between morphology and function (Swann, 1940). This 
correlation is clearly exemplified by syndromic disorders that feature 
adrenal dysplasia such as X-linked adrenal hypoplasia congenita and the 
Pallister-Hall syndrome (described more in depth in the third part of this 
review article and in Table 2), whereby disruption of the stereotypical 
zonal organization and cellular structure is accompanied by loss of 
steroidogenic activity. 
The cortical zona Glomerulosa (zG) clearly illustrates the tight cor-
relation between structure and function typical of the entire adreno-
cortical tissue. The zG is the outer zone of the adrenal cortex and is 
responsible for the synthesis of the mineralocorticoid aldosterone under 
the control of the Renin-Angiotensin-Aldosterone system (RAAS), high 
potassium levels and elevated blood pH. Aldosterone controls systemic 
salt and acid-base homeostasis by acting predominantly on the distal 
tubules and collecting ducts of the kidney to promote reabsorption of 
sodium and excretion of potassium and hydrogen ions (Bollag, 2014; 
Nishimoto et al., 2013). The zG is the smallest among the cortical zones 
and makes up about 15% of the entire adrenocortical tissue in humans 
and mice (Nussdorfer, 1980; Pignatti, 2014). Cells within the zG are 
arranged in round-shaped glomeruli surrounded by a basement mem-
brane, which separates glomeruli and cortical vasculature. While clas-
sical histological analysis may lead to the conclusion that zG glomeruli 
are isolated entities, 3D reconstruction recently revealed that glomeruli 
are tightly packed globular structures interconnected through openings 
in the basement membrane (Leng et al., 2020). Finally, each glomerulus 
contains one or more rosettes, defined as aggregates of five or more cells 
converging to one single center enriched in cadherin junctions. This 
structural framework is shaped and maintained in the mouse by the 
activity of the WNT and FGF signaling pathways, and shows a high level 
of conservation across species, suggesting it is critical to sustain zG 
function (Leng et al., 2020). Consistent with this hypothesis, recent 
studies bring clear evidence that steroid function and morphology 
within the zG are tightly linked. In this respect it is worth mentioning 
here a recent study by Guagliardo et al., which shows that calcium 
bursts, fundamental units of zG layer activity, display phase stability 
within each rosette. In mice, disruption of cadherin junctions within the 
rosettes reduces the number of clustered cells, the duration of evoked 
calcium bursts and, ultimately, leads to reduced aldosterone production 
(Guagliardo et al., 2020). The strong connection between morphology 
and function in zG is further substantiated by the expression of 
zone-specific genes with both structural and steroidogenic functions 
(extensively reviewed in Seccia et al., 2017). Some of these genes are 
also commonly used as markers in experimental animal models to 
determine zG identity. They include Disabled homolog 2 (DAB2) 
(Romero et al., 2007), Guanine nucleotide-binding protein G(q) subunit 
alpha (Gaq) (Pignatti et al., 2020; Taylor et al., 2020) and β-catenin 
(Basham et al., 2019; Berthon et al., 2010; Eberhart and Argani, 2001; 
Kim et al., 2008; Walczak et al., 2014). While Aldosterone Synthase 
(AS), encoded by the CYP11B2 gene, is also restricted to the zG, its 
expression is often confined to a subset of cells and its use as a zone 
marker may lead to underestimating the extent of the zG area (Bassett 
et al., 2004; Pignatti et al., 2017; Walczak et al., 2014). In spite of this, 
since AS expression levels are directly proportional to the systemic needs 
of aldosterone reflected by potassium and angiotensin levels in the cir-
culation (Heitzmann et al., 2008; Makhanova et al., 2006), it is 
reasonable to consider AS an indicator of zG activation. 
Concentric to the zG lies the zona Fasciculata (zF), which has strik-
ingly different functional and morphological properties than the zG. The 
zF occupies the largest fraction of the adrenal cortex and produces the 
glucocorticoid cortisol in humans (corticosterone in rodents). Cortisol is 
implicated in mobilization of protein, glucose and lipid depots to pro-
duce an adequate response to stress and hypoglycemia, and acts as an 
immunomodulatory agent inhibiting the production of a wide range of 
pro-inflammatory cytokines including interferon-gamma and tumor 
necrosis factor-alpha (Kadmiel and Cidlowski, 2013) while also being 
involved in immune cell recruitment, differentiation as well as activa-
tion (reviewed in Strehl et al., 2019). The enzymatic machinery resulting 
in cortisol production is activated by the cAMP/PKA signaling, which 
ultimately controls zF steroidogenic function by direct stimulation of 
critical enzymes, including Steroidogenic Acute Regulatory protein 
(StAR) and CYP11A1 (Ruggiero and Lalli, 2016). The Cyclic Adenosine 
Monophosphate/Protein Kinase A (cAMP/PKA) signaling pathway is 
initiated by binding of the polypeptide Adrenocorticotropin Hormone 
(ACTH) to its cognate G-protein coupled receptor MC2R. The accessory 
protein MRAP is essential for shuttling MC2R from the endoplasmic 
reticulum to the plasma membrane where it transduces ACTH signal 
(Metherell et al., 2005; Mountjoy et al., 1992). At a systemic level, ACTH 
is produced within the anterior pituitary gland under the control of the 
corticotropin releasing hormone (CRH), which in turn originates in the 
hypothalamic paraventricular nucleus. In addition to this 
hypothalamic-pituitary-adrenal (HPA) axis, cortisol secretion is also 
subject to a circadian rhythmicity entrained to the day-night cycle and to 
local, intra-adrenal circadian oscillators (Son et al., 2018). Besides, ad-
renal function is also under the control of the splanchnic nerve, which 
provides neural input to regulate differential steroid production upon 
stress or non-stress conditions (Engeland, 1998). The morphology of the 
zF differs from that of the zG in that cells are larger, less densely packed 
and much richer in lipid droplets. zF cells are organized in centripetal 
columns flanked by fenestrated blood vessels that facilitate the exchange 
of hormones, cholesterol and nutrients between the steroidogenic cells 
and the circulation (Lever, 1952). The steroid 11β-hydroxylase, encoded 
by CYP11B1, is a commonly used marker for the identification of the zF 
in human, rats and mice (Gomez-Sanchez et al., 2014; Ogishima et al., 
1992; Wotus et al., 1998). 
Finally, the zR represents the innermost cortical layer, lies at the 
interface with the adrenal medulla and is responsible for the production 
of high levels of androgens and androgen precursors in humans (Naka-
mura et al., 2012). Contrary to the outer zones, the zR is not present at 
birth and starts to progressively grow and assume its final shape during 
childhood, between the age of 6 and 9 in both boys and girls. The 
development of a functional zR and the consequent rise in circulating 
androgens is referred to as ‘adrenarche’ (Auchus, 2011). During adre-
narche, increased circulating androgens result in stereotypical systemic 
effects including growth of pubic and axillary hair and development of 
adult body odor. How the zR forms and what stimulates its development 
is still not clear, mainly because of lack of experimental models. Indeed, 
a functional zR is present in humans and has been thoroughly charac-
terized in rhesus macaques both morphologically and biochemically 
(Conley et al., 2011), while in Great Apes adrenarche has been inferred 
by the identification of fluctuating postnatal levels of androgen pre-
cursors (Conley et al., 2012; Nguyen and Conley, 2008). Lower species 
including the ferret and spiny mouse have also been recognized to 
produce adrenal androgens, although to what extent this activity reflects 
human adrenarche remains to be established (Lamers et al., 1986; Quinn 
et al., 2013; Rosenthal and Peterson, 1996). Overall, the existence of a 
zR in a subset of species suggests that unique molecular events are 
necessary for this zone to emerge (Conley et al., 2012). In this regard, a 
recent work from Martinez’s group shows that a functional zR-like tissue 
can develop in a zR-deficient mouse strain following overt activation of 
the cAMP/PKA signaling pathway (Dumontet et al., 2018). Whether the 
activation of the cAMP/PKA signaling explains adrenarche in humans 
and higher primates is still to be established, especially in consideration 
of the fact that ACTH, the main trigger of cAMP/PKA activity, does not 
raise in correlation with DHEA during adrenarche (Auchus and Rainey, 
2004). 
2.2. Aspects of prenatal development of the adrenal glands 
The adult adrenal cortex markedly differs in structure and function 
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Table 2 
Reported monogenetic causes of primary adrenal insufficiency and associated phenotype in humans.   
Disorder Gene OMIM Associated clinical features in addition to PAI 
Defects of steroid biosynthesis 
(e.g. congenital adrenal 
hyperplasia) 
Congenital lipoid adrenal 
hyperplasia (LCAH) 
StAR 201710 46,XY DSD, gonadal insufficiency  
P450 side chain cleavage syndrome 
(CAH) 
CYP11A1 118485 46,XY DSD, gonadal insufficiency  
3β-hydroxysteroid dehydrogenase 
deficiency (CAH) 
HSD3B2 201810 46,XY DSD and 46,XX DSD, gonadal insufficiency  
21-hydroxylase deficiency (CAH) CYP21A2 201910 46,XX DSD, androgen excess syndrome, testicular adrenal rest tumors  
11β-hydroxylase deficiency (CAH) CYP11B1 202010 46,XX DSD, hypertension, androgen excess syndrome  
17-hydroxylase deficiency (CAH) CYP17A1 202110 46,XY DSD, hypertension, gonadal insufficiency  
P450 oxidoreductase deficiency 
(CAH) 
POR 613571 46,XY DSD, 46,XX DSD, gonadal insufficiency, Antley-Bixler skeletal 
malformation syndrome; changes in drug metabolism  
Steroidogenic factor 1 deficiency NR5A1 (SF1) 184757 46, XY DSD, gonadal insufficiency  
Aldosterone synthase deficiency CYP11B2 124080 Isolated mineralocorticoid deficiency 
Adrenal dysgenesis (e.g. 
hypoplasia, agenesis) 




300200 Hypogonadotropic hypogonadism, in some cases gonadotropin 
independent precocious puberty  




IUGR, bone disorders and anomalies, genital anomalies, hypercalcemia, 
dysmorphic facial features, immunodeficiency  
MIRAGE syndrome SAMD9 617053 Myelodysplasia, infections, restriction of growth, genital anomalies, 
enteropathy  
SERKAL syndrome WNT4 611812 46,XX DSD, IUGR, cleft lip/palate, dysplastic kidneys and lungs, heart 
defects, diaphragmatic hernia, intestinal malrotation  
Pallister-Hall syndrome GLI3 165240 Hypothalamic hamartomas, mesoaxial and postaxial polydactyly, bifid 
epiglottis, imperforate anus, genitourinary anomalies  
Meckel syndrome MKS1 249000 Cystic renal disease, CNS malformation - occipital encephalocele, 
polydactyly, hepatic abnormalities  
Pena-Shokeir syndrome DOK7, RAPSN 208150 Arthrogryposis, facial anomalies, IUGR, camptodactyly, fetal akinesia, 
polyhydramnion, pulmonary hypoplasia, cardial defects, intestinal 
malrotation  
Pseudotrisomy 13  264480 Holoprosencephaly, polydactyly, craniofacial anomalies  
Hydrolethalus syndrome HYLS1 236680 Hydrocephaly, micrognathia, polydactyly abnormal genitalia, congenital 
heart defects, respiratory organ defects  
Galloway-Mowat syndrome WDR73 251300 Nephrotic syndrome, microcephaly, encephalopathy, hiatus hernia 






Mostly normal production of mineralocorticoids, tall stature  
FGD - Deficiency of mitochondrial 
ROS detoxification 
NNT 614736 Only glucocorticoid deficiency   
TXNRD2 606448 Only glucocorticoid deficiency   
GPX1  Only glucocorticoid deficiency   
PRDX3  Only glucocorticoid deficiency  
FGD - DNA repair defect MCM4 609981 NK cell deficiency, short stature, microcephaly, recurrent viral infections, 
chromosomal breakage  
AAA syndrome – Triple A (Allgrove 
syndrome) 
AAAS 231550 Alacrimia, achalasia, deafness, mental retardation, hyperkeratosis 
Cholesterol synthesis disorders Wolman disease LIPA 278000 Xanthomatous changes in the liver, adrenal, spleen, lymph nodes, bone 
marrow, small intestine and thymus, diffuse punctate adrenal calcification, 
hepatosplenomegaly, poor weight gain, hypercholesterolemia, steatorrhea  
Smith-Lemli Opitz disease DHCR7 270400 Multiple congenital malformation and mental retardation syndrome  
Abeta-lipoproteinemia MTP 200100 Ataxia, retinopathy, acanthocytosis, pathologic fat absorption  
Familial hypercholesterolemia LDLR 143890 Xanthomas, corneal arcus, and coronary artery disease  
Sitosterolemia (Phytosterolemia) ABCG5 
ABCG8 
210250 Short stature, gonadal failure, xanthomas, arthritis, coronary heart disease 





Progressive neurodegeneration, dementia, progressive behavioral 
disturbances, vision and hearing loss, spasticity and seizures; accumulation 
of very long chain fatty acids  
Neonatal adrenoleukodystrophy PEX1 601539 Hypotonia, seizures, diffuse encephalopathy, sensorineural hearing loss, 
peripheral neuropathy, mild facial dysmorphism; autosomal recessive  
Infantil Refsum disease PHYH, PEX7 266500 Anosmia, retinitis pigmentosa, neuropathy, deafness, ataxia, ichthyosis  
Zellweger syndrome PEX1 and other 
PEX genes 
214100 Severe neurologic dysfunction with handicaps, craniofacial abnormalities, 
severe mental retardation, hepatomegaly, growth failure, stippled 
epiphysis, genitourinary anomalies 
Mitochondrial defects Kearns-Sayre syndrome mitDNA del 530000 Progressive external ophthalmoplegia, pigmented retinopathy, cardiac 
conduction block, cerebellar ataxia; other endocrine pathologies  
(Combined) mitochondrial 
complex deficiency 
MRPS7 617872 Sensorineural deafness, liver and kidney failure, hypogonadism, 
neurodevelopmental delay. Lactic acidosis.  
(Leigh syndrome) NDUFAF5 612360 IUGR, brain anomalies and neurodegeneration resulting in 
neurodevelopmental delay, spasticity, chorea and seizures. Diaphragmatic 
hernia. Lactic acidosis.   
GFER 613076 Progressive myopathy with congenital cataract and developmental delay 
Lysosomal defect Sphingosine-1-phosphate lyase 1 
deficiency 
SPGL1 603723 Steroid-resistant nephrotic syndrome, optionally accompanied by 
ichthyosis, primary hypothyroidism, cryptorchidism, immunodeficiency 
and neurological defects 
Autoimmune disorder Autoimmune polyglandular 
syndrome type 1 (APS1, APECED) 
AIRE 240300 Hypoparathyroidism, candidiasis, autoimmune hypergonadotropic 
hypogonadism, autoimmune thyroid diseases alopecia, chronic 
autoimmune hepatitis, pernicious anemia, vitiligo  
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from the developing adrenal. Here we provide an overview of the genes 
and molecular pathways that are critical for the correct formation of the 
prenatal adrenal cortex. Most of this knowledge has been gained from 
studies in mice. Table 1 summarizes identified genes and reports on 
associated phenotypes when these genes are disrupted in mice and 
humans. 
The adrenal cortex originates around 28–30 days post conception 
(dpc), corresponding to embryonic day 9.5 (E9.5) in the mouse, from 
bilateral and symmetrical streaks of cells comprised between the 
coelomic epithelium and the dorsal aorta (Hatano et al., 1996). These 
cells form the adrenogonadal primordium (AGP) and express the pro-
genitor markers GATA4, Wilms’ tumor protein 1 (WT1) and 
Cbp/p300-interacting transactivator 2 (CITED2) (Bandiera et al., 2013; 
Val et al., 2007). WT1 is a zinc finger transcription factor, associated 
with a subset of early onset nephroblastomas, also known as Wilms’ 
tumor (Hohenstein and Hastie, 2006). Inactivation of WT1 in the mouse 
results in dysgenesis of several organs including the adrenal glands; this 
is due to a critical role of WT1 for the formation and maturation of the 
AGP, possibly because of the direct contribution of WT1 to the expres-
sion of SF-1 (Hohenstein and Hastie, 2006; Kreidberg et al., 1993, p. 1; 
Moore et al., 1999; Wilhelm and Englert, 2002). SF-1, encoded by the 
NR5A1 gene, is a transcription factor belonging to the nuclear receptor 
superfamily, essential for the differentiation of several organs, including 
gonads, spleen and adrenals (Luo et al., 1994). Contrary to GATA4, WT1 
and CITED2, SF-1 expression persists in all the steroidogenic cells of the 
adult adrenal cortex, where it controls the expression of several cyto-
chrome P450 steroid hydroxylases (Parker and Schimmer, 1997). Val 
and colleagues hypothesized that the specification of adrenal and 
gonadal lineages in the AGP is decided based on a threshold of SF-1 
expression, whereby SF-1 is stronger in the fraction of the AGP 
destined to become the adrenal cortex (Val et al., 2007). Consistent with 
this hypothesis, differential expression of SF-1 is achieved in the AGP 
thanks to the interaction of WT1 with the cofactor CITED2, which 
positively regulates WT1 transcriptional activity (Val et al., 2007). Other 
trans-acting factors have been involved in the regulation of SF-1, 
including the complexes of pre–B-cell leukemia transcription factor 1 
(PBX1) with the homeobox protein PKNOX1 and the homeobox proteins 
B9, B5 and C5 (HOXB9, HOXB5 and HOXC5, respectively). These 
complexes were shown to activate SF-1 in the AGP independent of WT1, 
by binding the fetal adrenal-specific enhancer (FAdE) located on the 4th 
intron of the NR5A1 gene (Zubair et al., 2006). 
Between 32 and 40 dpc (E10.5 in the mouse) the medial AGP sepa-
rates and migrates dorsally to become the adrenal primordium (Fig. 1). 
Around the same developmental time SF-1 expression becomes self- 
sustained in a positive feedback loop by trans-activation of NR5A1 
binding sites also present in the FAdE promoter (Zubair et al., 2006). In 
addition, genetic manipulation of WT1 expression in the mouse showed 
that WT1 must be shut down during the formation of the adrenal pri-
mordium to allow the progressive differentiation of the adrenal cortex 
(Bandiera et al., 2013). Indeed, overt activation of WT1 blocks the 
development and progressive differentiation of the adrenal by promot-
ing the expression of the transcription factors Gli1 and Tcf21, which are 
known markers of progenitor cells in both the developing and adult 
adrenal (Huang et al., 2010; King et al., 2009; Wood et al., 2013). 
Between 48 and 52 dpc (E12.5 in the mouse), a subset of neural crest 
cells migrate to form clusters within the adrenal primordium; these 
clusters later coalesce in the center of the adrenal gland and differentiate 
to active catecholamine-producing chromaffin cells, which form the 
adrenal medulla (Lumb and Schwarz, 2015). At the same time, mesen-
chymal cells surrounding the primordium form the adrenal capsule by 
creating a cell layer around the adrenal primordium (Mesiano and Jaffe, 
1997). After encapsulation, two morphologically different concentric 
zones can be identified within the adrenal primordium in humans and 
primates, the inner FZ and the outer and smaller ‘definitive zone’ or 
‘definitive cortex’ (DZ). The FZ, characterized by large lipid-loaded cells, 
is responsible for producing DHEA that is subsequently converted to 
estrogen by the placenta. Instead, the DZ is made of tightly packed, 
basophilic cells that remain almost inactive until the end of the second 
trimester of pregnancy, when this zone becomes a main hub of cortisol 
production (Goto et al., 2006; Hanley et al., 2001; Ishimoto and Jaffe, 
2011). Tracing experiments in mice showed that the emergence of the 
DZ is paralleled by the inactivation of the FAdE promoter but is still 
characterized by the expression of SF-1. The evidence for a Definitive 
adrenal-specific enhancer (DadE) that accounts for SF-1 expression in 
the later stages of development and in the adult adrenal is still missing. 
The cessation of the FAdE activity in the developing adrenal appears to 
rely at least on two molecular events, the SUMOylation of SF-1 and the 
co-repressive activity of the nuclear repressor protein dosage-sensitive 
Fig. 1. Embryonic adrenal development. Schematic illustration showing the cellular rearrangements during mouse and human adrenal development. The adre-
nogonadal primordium (AGP) originates from a streak of cells localized between the coelomic epithelium and the dorsal aorta (red arrow) around 28–30 dpc (E9.5). 
At 32–40 dpc (E10.5), the adrenal primordium separates from the AGP. Neural crest cells, precursors of the chromaffin cells of the medulla, invade the AGP between 
48 and 52 dpc (E12.5). From 56 dpc (E14.5) onward, the fetal cortical cells are slowly replaced by the definitive cortex, which gives rise to the zG and zF around the 
time of birth. 
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sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 
1 (DAX1) (Xing et al., 2017). DAX1 is a member of the nuclear receptor 
superfamily shown to act as a corepressor for SF-1 transcriptional ac-
tivity on numerous genes involved in adrenal development and ste-
roidogenesis (Ferraz-de-Souza et al., 2009; Lalli and Sassone-Corsi, 
2003; Lehmann et al., 2002; Li et al., 2011; Zhou et al., 2008). The 
gene encoding DAX1, NR0B1, was first cloned as the responsible gene 
for X-linked cytomegalic adrenal hypoplasia congenita (Mantovani 
et al., 2006). Inactivation of DAX1 in the mouse results in accelerated 
differentiation possibly due to premature exhaustion of adrenal pro-
genitor population, suggesting a role for this gene in regulating the 
balance between adrenal progenitor maintenance and recruitment/dif-
ferentiation (Scheys et al., 2011). Finally, while the descendants of the 
DZ will eventually give rise to zG and zF, soon after birth the FZ un-
dergoes a dramatic involution accompanied by a significant decrease in 
adrenal mass and a rapid fall in circulating DHEA and DHEA-S 
(Bocian-sobkowska et al., 1998; Bruch, 1936). 
2.3. Homeostatic maintenance and remodeling of the adult adrenal cortex 
2.3.1. A wide spectrum of progenitor populations 
Active endocrine tissues are characterized by a dynamic adaptation 
in size and function in response to systemic and local stimuli. In the adult 
adrenal cortex, remodeling depends on two main contributors: one, the 
recruitment of new steroidogenic cells from undifferentiated progenitors 
and two, the proliferation of differentiated cells. Historical autologous 
graft and pulse-chase experiments have validated a model in which 
adrenal renewal occurs in a centripetal fashion (Salmon and Zwemer, 
1941; Wyman and Walker, 1929). According to this model, cells from 
the capsule and subcapsular regions, including the zG, are progressively 
displaced in the most internal layers of the cortex up to the cortico-
medullary region, where they undergo cell death. Lineage tracing ex-
periments demonstrated that adrenocortical cells transdifferentiate 
during their centripetal migration by changing their morphology and 
function consistent with the zone they occupy. Therefore, capsular cells 
can give rise to zG cells, which can transdifferentiate into more internal 
zF cells. In turn, zF cells were shown to give rise to cells that reminisce 
the human zR in terms of molecular profile and steroidogenic potential 
(Dumontet et al., 2018; Freedman et al., 2013; Grabek et al., 2019; King 
et al., 2009). The origin of most adrenocortical cells from the outer re-
gions of the cortex is consistent with the presence of tissue-resident 
progenitors in the capsule and zG. This concept has been validated in 
mice using lineage tracing of discrete cell populations, specifically Gli1+
and Wt1+ cells (located in the adrenal capsule), and Sonic Hedgehog 
(Shh)+, Cyp11b2+, Axin2+ and Wnt4+ cells (located in the zG) (Ban-
diera et al., 2013; Freedman et al., 2013; Grabek et al., 2019; King et al., 
2009). Short-term fate mapping invariably displays these cells in the 
capsule or zG, consistent with the expression pattern of each marker, 
while long-term tracing identifies clusters/stripes of steroidogenic cells 
that progressively extend from the outer to the inner cortical regions, in 
agreement with their role as progenitor cells. Despite these common 
traits, the expression patterns of the distinct progenitor populations 
overlap only partially, or do not overlap at all, suggesting that a spec-
trum of different populations exist. In fact, Shh+ and Cyp11b2+ cells are 
subpopulations of Axin2-and Wnt4-expressing zG cells, whereas Wt1 
and Gli1 markers are expressed in the capsule and overlap only in a 
minority of cells (Bandiera et al., 2013; Grabek et al., 2019; Walczak 
et al., 2014). Besides, evidence is accumulating that distinct progenitor 
populations contribute to the steroidogenic compartment to different 
extents. This extent depends on multiple factors, including the intrinsic 
properties of each cell type (i.e. plasticity and quiescence status), the 
developmental stage of the adrenal, the sex of the animal and the 
presence of any regenerative stimulus that may lead to accelerated tissue 
turnover (reviewed in Hammer and Basham, 2021). For instance, pro-
genitor cells localized in the zG lead to a complete turnover of the ste-
roidogenic cortex within 3–6 months. In turn, capsular progenitors 
appear to act as reservoir stem cells prevalently recruited in response to 
supraphysiological demands, including regenerative/remodeling stim-
uli (Bandiera et al., 2013; Finco et al., 2018). However, a sexual 
dimorphic phenotype exists, since cell turnover in female adrenals still 
partially relies on the recruitment of capsular progenitors, while male 
adrenals maintain their homeostasis mainly by proliferation of differ-
entiated cells in the outer cortical regions (Grabek et al., 2019). This 
scenario indicates a notable heterogeneity among progenitor pop-
ulations, which ultimately serves the plasticity requirements of adrenal 
homeostasis and regeneration (Hammer and Basham, 2021; Walczak 
et al., 2014). 
2.3.2. Signaling pathways involved in the regulation of adrenal homeostasis 
While the relationship among the diverse progenitor cell populations 
might still be a matter of interesting debate and further investigation, 
the regulatory roles of the SHH, WNT and cAMP/PKA pathways in the 
regulation of adrenal homeostasis, regeneration and disease has been 
firmly established with the use of animal models of gene inactivation 
and hormonal treatment. The importance of these pathways in adrenal 
physiology is further corroborated by the pathological consequences of 
the disruption of critical signaling components, including GLI3 (Pallister 
Hall syndrome, linked to adrenal insufficiency; Table 2), β-catenin 
(adrenal hyperplasia and tumors) and cAMP-dependent protein kinase 
type I-alpha regulatory subunit (PRKAR1A, associated with primary 
pigmented nodular adrenocortical disease – PPNAD). Therefore, the 
SHH, WNT and cAMP/PKA pathways will be described briefly for their 
role in adrenal physiology. For a detailed coverage of the molecular 
aspects of these pathways and related disorder, the reader is addressed 
to more focused review articles (Blassberg and Jacob, 2017; Nusse and 
Clevers, 2017; Ruggiero and Lalli, 2016). 
In the adrenal, the SHH pathway is activated by the zG-secreted SHH 
ligand that binds its cognate receptor Patched 1 (PTCH1) expressed on 
the adrenal capsule. In turn, PTCH1 transduces the signal to the intra-
cellular transcription factors GLI, including GLI1, which is also 
expressed in the capsule (Bitgood and McMahon, 1995; Ching and 
Vilain, 2009; Huang et al., 2010; King et al., 2009). The peculiar 
expression pattern of the different components of the SHH pathway 
underlies a signaling bridge between the cortical zG and the capsule, 
which is key to the maintenance of adrenal progenitors. Indeed, 
disruption of the SHH pathway results in reduced adrenal mass caused 
by thinning of both the cortex and the capsule, which is consistent with 
loss of progenitor cells in both compartments (Ching and Vilain, 2009; 
Huang et al., 2010; King et al., 2009). 
Similarly, the WNT pathway is active thanks to a molecular crosstalk 
between capsule and cortex. The canonical form of the WNT pathway 
relies on the intracellular levels of β-catenin molecules, which act as 
signal transducers and co-factors in cooperation with the transcription 
factors of the TCF/LEF family. Levels of β-catenin are negatively regu-
lated by a multimeric destruction complex that targets serine and thre-
onine residues close to the N-terminal of the protein. Phosphorylation is 
commonly followed by ubiquitination and proteasomal degradation of 
β-catenin. Instead, when Wnt ligands engage the seven-transmembrane 
receptor Frizzled, the destruction complex is sequestered to the plasma 
membrane and β-catenin is free to accumulate in the cytosol and nu-
cleus, where it participates to the transcription of target genes. The ca-
nonical Wnt signaling is extensively regulated at the level of ligand- 
receptor interaction. For instance, Secreted Frizzled-related proteins 
(Sfrp and Frzb) and Wnt inhibitory factor (WIF) bind and sequester Wnt 
ligands away from their Frizzled receptor. In addition, Frizzled is 
constitutively targeted to degradation by the E3 ubiquitin ligase activity 
of RNF43 and ZNRF3, which are single-pass membrane proteins classi-
fied among the suppressors of Wnt signaling. In turn, RNF43 and ZNRF3 
are bound and internalized by the complex formed by membrane 
Leucine-rich repeat-containing G-protein coupled Receptor (LGR) 4/5/6 
and their ligands R-spondins (RSPOs), which overall provide an addi-
tional level of complexity to the regulation of the WNT signaling. 
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Despite this complexity, nuclear expression of β-catenin is a simple 
and validated indicator of active WNT signaling utilized both in diag-
nostic routine and animal studies (Basham et al., 2019; Eberhart and 
Argani, 2001; Walczak et al., 2014). In the adrenal, nuclear β-catenin 
and established WNT-target genes such as LEF1 and AXIN2 are 
expressed in the outer regions of the cortex in a gradient fashion, 
whereby WNT activity is stronger in the zG and weaker in the outer 
regions of the zF (Basham et al., 2019). This gradient of WNT activity is 
maintained by RSPO3, which is secreted by the adrenal capsule and 
binds the receptor LGR5 expressed in the outer cortical cells (Vidal et al., 
2016). In the mouse adrenal, the WNT signaling pathway is implicated 
in the preservation of the zG, by driving the expression of critical 
zG-specific differentiation markers (Berthon et al, 2010, 2014; Drelon 
et al., 2016; Leng et al., 2020; Pignatti et al., 2020), and in the main-
tenance of cell turnover in the cortex, by allowing the replenishment of 
the lost cortical cells (Kim et al., 2008). Consistent with this, disruption 
of the WNT pathway by inactivation of Rspo3 results in loss of zG 
markers within 24 h, and in halving of the adrenal mass within 6 weeks 
(Vidal et al., 2016). It is reasonable to speculate that these two functions 
of the WNT pathway are tightly linked, since the zG represents an 
important physical reservoir of progenitor cells for the entire cortex. 
The role of the WNT pathway in promoting and maintaining the zG 
identity is contrasted by the cAMP/PKA signaling pathway, which is 
prevalently active in the zF (Ruggiero and Lalli, 2016). As mentioned in 
the first section of this review article, the cAMP/PKA signaling pathway 
is initiated by binding of the polypeptide ACTH to the 
seven-transmembrane receptor MC2R. Signal transduction involves the 
release of the alpha subunit of the stimulatory G protein and the con-
version of adenosine triphosphate (ATP) into cAMP by the enzyme 
adenylyl cyclase. These events result in the dissociation of the regulatory 
subunit of PKA from its catalytic subunits, which in turn phosphorylate 
and activate multiple downstream signaling intermediates including the 
AMP-responsive element modulator (CREM) and the cAMP-responsive 
element binding protein (CREB) transcription factors. Among the four 
different PKA regulatory subunits identified in humans PRKAR1A has a 
particular clinical relevance, since null mutations in this gene result in 
overactivation of the pathway and lead to PPNAD, a rare hypersecretion 
disorder associated to the Carney complex syndrome (Groussin et al., 
2002). 
Over-activation of the cAMP/PKA signaling pathway in the mouse 
adrenal cortex results in reduced zG and increased zF differentiation and 
function (Drelon et al., 2016; Dumontet et al., 2018; Sahut-Barnola 
et al., 2010). Although the molecular bases are not known, this effect is 
likely mediated by the suppression of WNT4, the most characterized 
WNT ligand expressed in the zG. Indeed, inactivation of Wnt4 pheno-
copies cAMP/PKA activation, in that it results in decreased Axin2 and 
Lef1 transcripts (zG markers) and expanded zF territory (Drelon et al., 
2016). 
Phosphodiesterases are selective inhibitors of the cAMP/PKA 
pathway for their capacity of hydrolyzing cAMP to inactive AMP, and 
may also play a role in establishing zG/zF zonation by inhibiting zF 
differentiation. A recent study indicates that the cGMP-dependent 3′,5′- 
cyclic phosphodiesterase encoded by the Pde2a gene is expressed within 
the mouse zG and is a direct target of the WNT pathway, which opens the 
possibility that PDE2A suppresses the cAMP/PKA signaling in the zG and 
inhibits the expression of zF markers (Pignatti et al., 2020). Another 
evidence that supports the role of phosphodiesterases in the inhibition of 
the cAMP/PKA adrenal signaling comes from the mouse model of ad-
renal insufficiency caused by disruption of the Ezh2 gene, which encodes 
a histone methyltransferase (Mathieu et al., 2018). Indeed, Ezh2-defi-
cient female mice show increased ectopic expression of the phosphodi-
esterases PDE1B, 3A, and 7A in the zF, and display diminished zF 
differentiation and expansion of the zG territory. Besides, inactivation of 
Ezh2 also leads to reactivation and expansion of GATA4 and WT1 fetal 
markers, which is indicative of ongoing dedifferentiation of adrenal cells 
to a progenitor-like state (Mathieu et al., 2018). Altogether, these results 
provide evidence for a role of adrenal phosphodiesterases in adult ad-
renal zonation and steroidogenesis. 
3. Adrenal steroidogenesis 
3.1. Steroidogenesis of the human adult adrenal cortex 
Suggested by the concept of functional zonation, the structural 
characteristics of each adrenal zone are instrumental to produce distinct 
steroid hormones. Fig. 2 provides an overview of the steroidogenic ac-
tivity within each zone of the human adrenal. It shows genes/enzymes 
and cofactors involved in the stepwise conversion of cholesterol into the 
three key steroid pathways leading to mineralocorticoids in the zG, 
glucocorticoids in the zF and adrenal androgens in the zR. 
All cortical steroids are synthetized from cholesterol which is either 
stored in esterified form or freely available within cells for steroid pro-
duction (Miller, 2017). Cholesterol recruitment from endosomes and 
lipid droplets seems to involve proteins encoded by STARD3, 
STARD3NL, Niemann Pick type C 1 (NPC1) and NPC2 (reviewed in 
Gallo-Payet and Battista, 2014). Steroidogenesis is carried out by mon-
ooxygenases of the cytochrome P450 family and hydroxysteroid de-
hydrogenases located in the endoplasmic reticulum and in mitochondria 
(Miller and Auchus, 2011). Shuttling of cholesterol to the mitochondria, 
and from there to the inner mitochondrial membrane are the initial and 
limiting steps for the biosynthesis of all adrenal steroids (Miller, 2017; 
Miller and Auchus, 2011). Despite the exact mechanisms underlying 
these processes have not been completely clarified, it is established that 
the StAR is responsible for shuttling about 90% of the cholesterol present 
in the inner mitochondrial membrane (Miller, 2017). Here, cholesterol is 
converted to pregnenolone by the side-chain cleavage enzyme, encoded 
by the CYP11A1 gene and supported by cofactors adrenodoxin (FDX1) 
and the enzyme adrenodoxin reductase (FDXR). While StAR and 
CYP11A1 are ubiquitously expressed within the adrenal cortex, the 
zonal segregation of other enzymes accounts for the compartmentali-
zation of steroid production (Nishimoto et al., 2012; Rege et al., 2014). 
Within the zG, aldosterone is the product of sequential processing of 
pregnenolone into progesterone, 11-deoxycorticosterone and cortico-
sterone, with the enzymatic reactions driven by 3β-hydroxysteroid de-
hydrogenase (HSD3B2), 21-hydroxylase (CYP21A2) and CYP11B1, 
respectively (Fig. 2). AS, encoded by the CYP11B2 gene, catalyzes the 
limiting and final step of aldosterone biosynthesis, and is expressed in 
patchy pattern selectively within the zG (Pignatti et al., 2017). CYP11B2 
is quickly regulated by aldosterone-releasing stimuli (e.g. Angiotensin II, 
elevated potassium and blood pH), which trigger the expression of 
CYP11B2 transcripts and proteins through rapid intracellular bursts of 
calcium and activation of the Calcium/calmodulin-dependent protein 
Kinases (CaMKs) (Guagliardo et al., 2020). This highly reactive and 
dynamic system offers a rapid way to control blood pressure and pH by 
almost instant release of aldosterone and is systemically controlled by 
the renin-angiotensin feedback loop. 
Within the zF, cortisol production depends on the expression of the 
17α-hydroxylase enzyme, encoded by the CYP17A1 gene, which con-
verts pregnenolone into 17α-hydroxypregnenolone. The following 
downstream enzymatic reactions result in the formation of 17α- 
hydroxyprogesterone, 11-deoxycortisol and cortisol, and are mediated 
by HSD3B2, CYP21A2 and CYP11B1, respectively (Fig. 2). Cortisol 
release is rapidly induced following the activation of the HPA stress 
response, and its expression largely depends on ACTH via the cAMP/ 
PKA signaling-mediated stimulation of critical enzymes, including 
CYP11A1 and StAR transcripts (Ruggiero and Lalli, 2016). 
Output of the human zR, mainly DHEA, DHEA-S and 11β-hydrox-
yandrostenedione, is due to the low expression of the HSD3B2 gene, the 
enhanced activity of the 17,20-lyase function of CYP17A1 and the 
increased expression of the sulfotransferase SULT2A1. Combined, these 
molecular events are hallmarks of the zR and herald adrenarche. 
CYP17A1 has both a hydroxylase and a lyase activity. Phosphorylation 
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of CYP17A1 and the concomitant expression of the allosteric regulator 
cytochrome b5 favor the lyase activity, which facilitates the conversion 
of 17α-hydroxypregnenolone to DHEA (Auchus et al., 1998; Zhang et al., 
1995). SULT2A1 drives the conversion of DHEA to DHEA-S with the 
support of the co-substrate 3′-phosphoadenosine 5′-phosphosulfate 
(Noordam et al., 2009; Weinshilboum et al., 1997). It is important to 
note that adrenal steroidogenesis of the human adrenal cortex differs 
from steroidogenesis of a rodent’s adrenal cortex mainly because of 
species-specific expression of CYP17A1 (Miller, 2017; Miller and 
Auchus, 2011). As mouse adrenals do not normally express Cyp17, they 
produce corticosterone, while human adrenals also produce cortisol and 
C19 steroids. 
DHEA and its sulfated metabolite are the most abundant adrenal 
androgens, but they are bioinactive and mainly serve as substrate for 
peripheral conversion into more potent androgens. But recent evidence 
shows that bioactive androgens including testosterone and 11-oxy an-
drogens are also produced within the adrenal glands via the catalytic 
activities of the type 5 17β-hydroxysteroid dehydrogenase encoded by 
the AKR1C3 gene and the CYP11B1 hydroxylase (Fig. 2) (Nakamura et 
al, 2009, 2012). Among the bioactive androgens, 11-hydroxyandroste-
nedione was found to be the second most abundant and with relevant 
bioactivity at the androgen receptor either itself or after peripheral 
conversion to highly bioactive androgens 11-ketotestosterone and 
11-ketodihydrotestosterone (Turcu et al., 2020). 
In addition, the adrenals during the period of fetal sexual maturation 
as well as with disorders of adrenal steroidogenesis have been recog-
nized as a hub for production of alternative active androgens through 
the ‘backdoor pathway’ (Fig. 2) (Biason-Lauber et al., 2013; Fukami 
et al., 2013; Kamrath et al., 2013; Reisch et al., 2019). Together with the 
‘classic’ DHEA-mediated pathway, the backdoor pathway is involved in 
the production of active androgens in disorders of steroidogenesis and 
sex differentiation of both 46,XY and 46,XX fetuses. More in detail, the 
backdoor pathway has been first described in tammar wallaby pouch 
offspring (Auchus, 2004; Wilson et al., 2003). It leads to the production 
of dihydrotestosterone from 17α-hydroxyprogesterone via the enzymes 
5α-reductase (SRD5A1), Aldo-keto reductase family 1 member C2 and 
C4 (AKR1C2, AKR1C4), CYP17A1, AKR1C3 and 17β hydroxysteroid 
dehydrogenase 6 (HSD17B6) through a number of alternative interme-
diate steroid metabolites not comprised in the classic pathway (Flück 
et al., 2011; Wilson et al., 2003). 
Importantly, the function of all monooxygenases of the cytochrome 
P450 family involved in steroidogenesis critically depends on the 
reducing capacity of two co-factors, the FDXR, embedded in the inner 
mitochondrial membrane, and the Cytochrome P450 Reductase (POR), 
localized to the membrane of the endoplasmic reticulum (Pandey and 
Sproll, 2014; Sheftel et al., 2010). While POR directly transfers redox 
equivalents from Nicotinamide Adenine Dinucleotide Phosphate 
(NADPH) to microsomal cytochrome P450 proteins, FDXR first transfers 
electrons to two forms of adrenodoxin, encoded in humans by the FDX1 
and FDX2 genes, which in turn reduce the target mitochondrial enzymes 
(Hanukoglu, 2017). The critical role of POR in steroidogenesis is 
underscored by the consequences of pathogenic genetic variations in the 
POR gene, which are associated with disorders of steroid production and 
sexual development (Table 2). On the other hand, FDXR insufficiency in 
human is linked with auditory neuropathy and optic atrophy (Paul et al., 
2017), while its pathological role in steroidogenesis still needs to be 
clearly determined. 
Fig. 2. Adrenal steroid biosynthesis in humans. The adrenal cortex is structured into three concentric zones, which produce specific steroids. Mineralocorticoids 
(MC) are synthesized in the outermost layer (zona glomerulosa); glucocorticoids (GC) are produced in the middle layer (zona fasciculata); and androgens (AA) are 
produced in the inner layer (zona reticularis). The scheme provides an overview of the biochemical pathways leading to the three main groups of steroids and shows 
intermediate products as well as involved enzymes and cofactors catalyzing stepwise conversion of cholesterol into specific products. Enzymes expressed in all zones 
are colored in grey, while enzymes essential for the production of a specific class of steroids are given in green for the MC path, red for the GC path and blue and 
purple for the AA path. In the AA path enzymes included in the classic and 11-oxyandrogen path are given in blue, enzymes of the alternative backdoor path in 
purple. Steroids that are normally produced in the adult adrenal cortex are given in bold, while steroids that are not usually produced in relevant quantities are given 
in normal font. 
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3.2. Steroidogenesis of the fetal adrenal 
Data on ontogeny of the steroidogenic activity of the human fetal 
adrenal result from hormonal measurements from cord blood, amniotic 
fluid and tissues as well as expression profiling of involved genes (e.g. 
steroid enzymes). These data have been comprehensively reviewed 
elsewhere (Ishimoto and Jaffe, 2011; Mesiano and Jaffe, 1997). 
In contrast to the adult adrenal cortex, steroid biosynthetic function 
of the fetal adrenal seems less diverse with prominent DHEA and DHEA- 
S production starting at around 8–10 weeks of gestation and rising 
thereafter constantly to reach abundant levels of about 200 mg/day at 
the end of pregnancy (Ishimoto and Jaffe, 2011). This is mainly due to 
expression of CYP11A1 and CYP17A1 and their redox partners in the 
relative absence of HSD3B2 throughout most of pregnancy in the ad-
renal FZ, which comprises most of the steroidogenic activity. However, 
enabled by spatiotemporal specific expression of HSD3B2, relevant 
levels of cortisol are also produced in a narrow time window in the first 
trimester (8–12 weeks gestation). This seems important for safeguarding 
the female external genitalia from virilization as exemplified by 46,XX 
girls with congenital adrenal hyperplasia due to pathogenic CYP21A2 
variants causing ambiguous genitalia, and their successful treatment 
with dexamethasone (Goto et al., 2006). In the second trimester cortisol 
synthesis occurs only indirectly through the use of placental derived 
progesterone entering the circulation and then being further metabo-
lized to cortisol in the fetal adrenals (Johnston et al., 2018). This 
continued cortisol production into the second trimester seems necessary 
for normal homeostatic feedback regulation and programming of the 
HPA, stress hormone axis. Only after 24–28 weeks gestation and espe-
cially towards late gestation intra-adrenal direct cortisol production 
resumes to prepare the fetus (e.g. the lungs) for postnatal life. By 
contrast, fetal adrenals do not produce aldosterone until late gestation 
due to lack of CYP11B2 expression (Ishimoto and Jaffe, 2011; Johnston 
et al., 2018). Shortly before term, the DZ of the fetal adrenal is the 
location where aldosterone production starts. Cells of the DZ will then 
develop into the zG and zF of the postnatal adrenal cortex due to 
expression of CYP11A1 and CYP17A1 and their redox partners in the 
relative absence of HSD3B2. 
It is noteworthy that the function of the fetal adrenal needs to be seen 
in a wider context with the feto-placental unit and other fetal organs (e. 
g. liver, testis) that all participate in the steroid intermediate metabolism 
(Ishimoto and Jaffe, 2011). Steroids produced by the fetal adrenal and 
progesterone produced by the placenta, play essential roles in the 
maintenance of pregnancy, intrauterine homeostasis, fetal (sex) devel-
opment and maturation, as well as the initiation of parturition. Adrenal 
androgens DHEA/DHEAS are precursors for placental estrogen produc-
tion. However, recent studies show that they also serve as substrate for 
5α-androsterone production by the placenta (O’Shaughnessy et al., 
2019). Likewise, 5α-17OH-pregnanolone produced in the placenta, fetal 
testis or liver can be metabolized to 5α-androsterone in the fetal adrenals 
in a sex dimorphic fashion. Together with testosterone 5α-androsterone 
has been identified as a key player of normal male sex development. On 
the other hand progesterone produced by the placenta has also been 
reported to be a precursor for cortisol production in the second 
trimester, since fetal adrenals lack HSD3B2 activity (Johnston et al., 
2018). 
Expression of genes determining fetal adrenal steroidogenesis is 
regulated by transcription factors. Among them SF-1/NR5A1 and 
DAX1/NR0B1 play crucial roles for organogenesis of the adrenal cortex 
from earliest stages on (see also 2.1.). But SF-1 is also a major tran-
scriptional activator of several genes of steroidogenesis, including STAR, 
CYP11A1, CYP17A1, CYP21A2, HSD3B2, CYP11B, SULT2A1. By 
contrast, DAX1 is an opponent of SF-1 stimulated transactivation. 
Transcription factors of the Nur family (e.g. NGFI-B, NURR1) regulate 
expression of HSD3B2, CYP21A1 and HSD11B2 and thus dictate fetal 
adrenal steroidogenesis fundamentally. But regulators of NGFI-B 
expression are unknown. Several other transcription factors such as 
GATA4, GATA6, CITED2, PBX1 and COUP-TFII have been related to 
adrenal development, but their role in regulating adrenal steroidogen-
esis is not entirely clear (Johnston et al., 2018). 
4. Disorders of human adrenal development and function 
Genetic disorders affecting human adrenal development and/or 
steroidogenesis lead to primary adrenal insufficiency (PAI), which is 
clinically defined by cortisol deficiency. Table 2 summarizes currently 
described monogenetic causes of PAI and their associated phenotype. 
Disorders that affect not only the adrenals and steroidogenesis but 
disrupt also other organ functions are called syndromic forms. They 
include metabolic disorders of cholesterol synthesis, peroxisomal, 
mitochondrial and lysosomal defects as well as the autoimmune poly-
glandular syndromes, which will not be discussed in detail as they 
mostly do not primarily affect adrenal development and typically start 
off with normal adrenal function. The following sections will focus on 
genetic disorders (non-syndromic and syndromic) leading to adrenal 
dysgenesis, hyperplasia and deficient adrenal steroid biosynthesis in the 
first place (as summarized in the first part of Table 2). Several reviews on 
PAI have been published in the last 3 years (Buonocore and Achermann, 
2020; Fluck, 2017; Guran, 2017; Hannah-Shmouni and Stratakis, 2018; 
Maharaj et al., 2019; Miller, 2018; Roucher-Boulez et al., 2018). 
4.1. Congenital adrenal hyperplasia (CAH) 
Genetic disorders of adrenal steroidogenesis leading to cortisol 
deficiency are better known as CAH because the resulting ACTH over-
production will stimulate adrenal cortex growth through proliferation of 
adrenocortical cells (Miller et al., 2020; Stewart and Newell-Price, 
2016). In case of STAR deficiency, additional intracellular lipid accu-
mulation will lead to lipoid CAH. Structurally, the development of the 
three zones of the adult adrenal cortex seems unaffected by congenital 
steroid biosynthetic defects although little evidence exists. To date, ge-
netic disorders related to each step of the classic steroid biosynthetic 
pathway have been described and are principally characterized by 
clinical signs and biochemical markers of related deficiencies of down-
stream steroid hormones and upstream precursor excess (Fig. 2 and 
Table 2). However, clinical diagnosis of CAH may be more complicated 
than theoretically thought as some enzymes are able to catalyze multiple 
reactions (also in extraadrenal tissues), have partial activity and sup-
porting cofactors. They can therefore lead to a disease pattern that may 
be only recognized by comprehensive phenotyping and steroid profiling 
using chromatographic mass spectrometric methods. Moreover, a final 
genetic diagnosis should be attempted in all cases because similar phe-
notypes may be caused by variants in more than one gene and vice versa. 
In the following section some aspects of specific CAHs will be discussed. 
For a more comprehensive description of the specific clinical findings of 
all CAHs, we refer to medical textbooks, e.g. (Miller et al., 2020; Stewart 
and Newell-Price, 2016). 
The first CAH described in the medical literature and solved to the 
molecular genetic level was 21-hydroxylase deficiency due to autosomal 
recessive, pathogenic variants of the CYP21A2 gene (Miller, 2013). It is 
also the most frequently occurring form of CAH with a worldwide 
incidence of its classic form in about 1 in 10′000–15′000 newborns 
(Miller and Auchus, 2011; Stewart and Newell-Price, 2016). Numerous 
pathogenic variants have been reported in affected persons with very 
good genotype-phenotype and structure-function correlation. Loss of 
21-hydroxylase activity in its severest form leads to aldosterone and 
cortisol deficiency and adrenal androgen excess (Fig. 2). Milder forms 
that retain some enzyme activity might only lead to a relative cortisol 
deficiency, but a constant androgen excess, and are known as 
non-classic, late-onset CAH. As the first trimester fetal adrenals are 
supposed to produce cortisol to lower ACTH and thereby adrenal 
androgen production for the prevention of masculinization of female 
fetuses, girls with 21-hydroxylase deficiency will not be able to produce 
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cortisol and will therefore be born with variable degrees of virilized 
external genitalia reflecting the degree of CYP21A2 enzyme deficiency 
and intrauterine androgen excess. Androgen excess of 21-hydroxylase 
deficiency pre- and postnatally has been shown to result from 
17-hydroxyprogesterone excess feeding into the alternative backdoor 
pathway of androgen biosynthesis as well as the pathway of 11-oxyan-
drogens (Kamrath et al, 2013, 2018) (Fig. 2). 
Similarly, pathogenic variants in the CYP11B1 gene will result in 
cortisol deficiency and androgen excess, but because the enzyme block 
lies one step downstream marker steroids comprise 11-deoxycorticoster-
one and 11-deoxycortisol. Accumulation of 11-deoxycorticosterone, 
which is an active mineralocorticoid, will lead to hypertension over 
time. By contrast, genetic mutations of the CYP11B2 enzyme supporting 
the last step of aldosterone production in the zG cause isolated miner-
alocorticoid deficiency without affecting cortisol production, and 
therefore do not actually belong to the group of CAH. 
Genetic disorders of the initial steps of adrenal steroidogenesis 
include STAR and CYP11A1 deficiencies, which are essential for the 
production of all adrenal steroid hormones (Fig. 2) (Miller, 2017; Miller 
et al., 2020). STAR is the cholesterol shuttler to the mitochondria where 
in the inner membrane the side chain cleavage system consisting of 
CYP11A1 and cofactors FDX and FDXR will convert cholesterol to 
pregnenolone. Severe STAR deficiency is responsible for lack of steroid 
hormone production by the adrenals and gonads, but not the placenta in 
which mitochondrial STAR import occurs through other mechanisms 
(Miller, 2017). In dependent organs, about 86% of cholesterol import is 
STAR-dependent, allowing minimal residual steroid production at first. 
However, this has been shown to disappear over time due to massive 
intracellular lipid accumulation and consecutive cell destruction, 
described in the literature as second hit (Miller, 2017; Miller et al., 
2020). Persons with classic lipoid CAH are unable to synthesize corti-
costeroids and sex hormones. Thus karyotypic 46,XY male fetus will not 
only suffer from PAI, but will also present with female typical external 
genitalia at birth as lack of intrauterine (testicular) androgen production 
will fail to support normal masculinization. Later on, pubertal devel-
opment and fertility will be affected in both sexes, although the ovary 
might show some functionality initially as its second hit is delayed to 
puberty since it is functionally quiescent during fetal life. 
Severe enzyme deficiency of CYP11A1 is clinically indistinguishable 
from STAR with the exception that it does not lead to lipid accumula-
tion. Interestingly, milder non-classic forms of both STAR and CYP11A1 
deficiencies exist and lead to PAI without affecting sex hormone 
production. 
Autosomal recessive mutations of HSD3B2 also affect all three 
pathways of adrenal steroidogenesis and gonadal steroidogenesis. 3β- 
hydroxysteroid dehydrogenase deficiency leads to an accumulation of 
C19 steroids produced over the delta 5 pathway (pregnenolone, 17- 
hydroxyprenenolone, DHEA; Fig. 2), which may result in female virili-
zation while not providing sufficient precursors for proper testosterone 
production and male masculinization (Burckhardt et al., 2015; Miller 
et al., 2020). 
The enzyme CYP17A1 has two catalytic properties, e.g. 17-hydroxy-
lase activity allowing pregnenolone and progesterone to enter the 
cortisol biosynthetic pathway, and 17,20 lyase activity for the synthesis 
of adrenal DHEA (Fig. 2). Most pathogenic variants of CYP17A1 cause 
deficiency of both enzymatic functions and manifest with low cortisol 
and sex hormone levels, but elevated mineralocorticoids. Only very few 
specific variants lead to isolated 17,20 lyase deficiency and thus cause 
isolated lack of sex hormone production. Cytochrome b5 (CYB5) and 
POR are essential cofactors supporting 17,20 lyase activity. Mutations of 
POR and CYB5 may therefore copy the phenotype of isolated 17,20 lyase 
deficiency. Likewise, mutations in backdoor genes AKR1C2/4 have been 
reported with similar phenotypes (Biason-Lauber et al., 2013), and 
similar phenotypes have also been observed with some (heterozygous) 
variants in the SF-1/NR5A1 gene (Fabbri-Scallet et al., 2020). 
Finally, genetic variants of cofactor POR can cause non-syndromic as 
well as syndromic PAI (Fluck et al., 2004). POR supports all microsomal 
type 2 P450 enzymes including steroidogenic CYP17A1, CYP21A2 in the 
adrenals and CYP19A1 in estrogen producing tissues (e.g. placenta, 
ovary) (Pandey and Fluck, 2013). Thus, POR mutations will show an 
adrenal steroid profile resembling combined CYP17 and CYP21 defi-
ciency. In most cases, it will also cause atypical sex development in both 
sexes through inadequate androgen production involving the classic and 
backdoor androgen biosynthetic pathways as well as placental androgen 
to estrogens conversion. Maternal virilization in POR deficiency un-
derscores the importance of the interplay of fetal adrenal steroidogen-
esis with the feto-placental unit (Fluck et al., 2020). The severest 
phenotype of genetic variants in POR manifest as Antley Bixler syn-
drome (ABS), which is characterized by craniosynostosis, radiohumeral 
synostosis, PAI and ambiguous genitalia. The skeletal phenotype of POR 
deficiency can be explained by its effect on interacting P450s of 
cholesterol biosynthesis (e.g. CYP51A1) as well as retinoic acid meta-
bolism (e.g. CYP26B1) that are critical for bone formation (Fluck and 
Pandey, 2013). 
4.2. Adrenal hypoplasia congenita (AHC) 
Pathogenic variants or deletion of the transcription factor DAX1 
encoded by the NR0B1 gene and located on chromosome Xp21 cause X- 
linked AHC. In this most common form of primary adrenal hypoplasia in 
boys, the DZ of the fetal adrenal does not develop, and the FZ is vacu-
olated and cytomegalic (Miller et al., 2020; Suntharalingham et al., 
2015). Affected boys suffer from salt-loss and cortisol insufficiency 
either in early infancy or childhood. Mutations of DAX1/NR0B1 also 
cause hypogonadotropic hypogonadism with incomplete pubertal 
development. NR0B1 gene deletions may be part of a contiguous gene 
deletion syndrome variably including a mental retardation gene 
(IL1RAPL1) and genes for glycerol kinase deficiency (GKD) as well as 
ornithine transcarbamylase (OTC) and Duchenne muscular dystrophy 
(DMD). 
Surprisingly, human mutations in SF-1/NR5A1, the master tran-
scription factor for adrenal and gonadal development and steroidogen-
esis, only very rarely lead to PAI (Suntharalingham et al., 2015). In the 
broadest sense, it might therefore also be classified as a form of adrenal 
hypoplasia. However, most human SF-1 mutations affect the gonads and 
sex development only. By contrast, Nr5a1 knockout mice reveal adrenal 
agenesis, gonadal (testicular) dysgenesis with a XY female phenotype 
and persistent Müllerian structures (uterus). They also have hypo-
gonadotropic hypogonadism and hyposplenism (Suntharalingham et al., 
2015). 
4.3. Familial glucocorticoid deficiency (FGD) 
FGD or ACTH unresponsiveness/resistance syndromes comprise 
another group of monogenetic disorders causing PAI (Table 2). Grossly 
elevated ACTH and very low levels of cortisol are characteristic clinical 
findings. Mutations of the ACTH receptor (MC2R) were the first un-
derlying genetic causes identified in non-syndromic FGD (Clark et al., 
1993), while mutations in the MRAP gene (Metherell et al., 2005) 
required for proper function and transport of the MC2R protein to the 
cell membrane location followed (Miller et al., 2020). They manifest 
early in life with mostly isolated glucocorticoid deficiency and hyper-
pigmentation (due to massive ACTH stimulation of MC1R receptors in 
the skin). FGDs are also characterized by absent adrenarche owing to 
low adrenal androgen production informing on the essential role of 
ACTH signaling for zR functionality (Novoselova et al., 2019). Adrenal 
glands are small and the cortex consists of a disorganized zG without zF 
and zR (Clark and Weber, 1998). Recent studies in Mrap− /− KO mice 
mimicking the human FGD phenotype revealed grossly dysmorphic 
adrenals with thickened capsule, deranged zonation and deranged 
WNT4/β-catenin and SHH signaling (Novoselova et al., 2019). 
FGD may also be caused by pathogenic variants in genes involved in 
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the reactive oxygen species (ROS) detoxification and energy transfer 
system of the respiratory chain in mitochondria (Maharaj et al., 2019). 
Obviously adrenal steroid biosynthesis relies heavily on this system. The 
first mutations in a gene of this kind discovered in a relevant number of 
patients with FGD were found in Nicotinamide Nucleotide Trans-
hydrogenase (NNT) (Maharaj et al., 2019). NNT reduces NADP + at the 
expense of NADH oxidation and H+ movement down the electro-
chemical potential across the inner mitochondrial membrane. Lack of 
NNT activity in Nnt null mice impairs peroxide metabolism in intact 
mitochondria, and hence increases oxidative stress, which seems to 
impede steroidogenesis. Adrenal histology shows mild hyperplasia and 
disorganization of the zF, but otherwise normal zonation and steroid 
enzyme expression. Likewise, genetic variants of thioredoxin reductase 
2 (TXNRD2), glutathione peroxidase 1 (GPX1) and peroxiredoxin 3 
(PRDX3) comprised in the thioredoxin and glutathione redox systems 
were found in patients with a profile of FGD/PAI (Table 2). Txnrd2 null 
mice exhibit embryonic lethality with severe growth restriction, cardiac 
and hematopoietic anomalies but no adrenal defects were reported 
(Maharaj et al., 2019). 
4.4. Syndromic forms of PAI affecting adrenal structure and function 
Although it would be conceivable that many genetic disorders 
identified in syndromic PAI might overlap with genes involved in fetal 
and adult adrenal development, there is in fact only little overlap so far. 
This might be due to the fact that such genetic defects are embryonic 
lethal or that they have simply not yet been identified. One such syn-
drome is the SERKAL syndrome caused by recessive mutations in the 
WNT4 gene (Mandel et al., 2008). It has so far only been reported in two 
aborted fetuses of a consanguineous family. According to WNT4 
signaling playing essential roles in organogenesis (see Table 1), fetuses 
revealed multiple defects including female to male sex reversal and 
kidney, adrenal, and lung dysgenesis. Discrepancies between genes 
involved in PAI and adrenal development can also be ascribed to the fact 
that most developmental genes have been investigated in the mouse, and 
it is plausible that some genes identified in mouse studies are not 
involved in human adrenal development and organization. 
Two syndromic forms of PAI have been found among persons man-
ifesting at first with an FGD phenotype, namely the triple A syndrome 
(AAAS) and the minichromosome maintenance 4 (MCM4) syndrome. 
Triple A (also known as Allgrove) syndrome combines PAI with 
Achalasia of the esophagus, Alacrima. However (progressive) neuro-
logical symptoms are also found in most triple A patients including in-
tellectual impairment, sensorineural deafness, peripheral and cranial 
neuropathies, optic atrophy, parkinsonism and autonomic dysfunction 
(Huebner et al., 2000; Miller et al., 2020). Alacrima and dysphagia are 
usually the first clinical signs. Cortisol deficiency is found in most pa-
tients, but manifests typically not before adulthood, while mineralo-
corticoid insufficiency is only rarely encountered. Triple A syndrome is 
due to autosomal recessive variants in the AAAS gene (12q13) coding for 
the ALADIN nuclear pore scaffolding protein (Handschug et al., 2001). 
ALADIN interacts with ferritin heavy chain protein FTH1 during nuclear 
translocation that renders cells susceptible to oxidative damage. Defi-
ciency of ALADIN impairs the redox potential of adrenal cells and in-
hibits steroidogenesis. ALADIN is also involved in the regulation of 
formation of the mitotic spindle. Remarkably, lack of ALADIN in mice 
does not recapitulate the triple A syndrome phenotype with normal 
structure and function of adrenals (Huebner et al., 2006). 
MCM4 mutations were found with FGD in the Irish Traveler popu-
lation exclusively (Hughes et al., 2012). The syndrome is characterized 
by isolated cortisol deficiency, growth failure, increased chromosomal 
breakage, and natural killer cell deficiency. Patients with MCM4 mu-
tations are susceptible to infections and might carry a higher tumor risk. 
MCM4 plays a role in DNA replication control (i.e. S-phase). Mcm4 null 
mice are embryonic lethal, but hypomorphic Mcm4 mutant mice survive 
and recapitulate the human phenotype showing abnormal, 
non-steroidogenic adrenals (Hughes et al., 2012). 
Several other syndromes have PAI included in their spectrum either 
showing adrenal agenesis or dysplasia (Table 2). But the exact mecha-
nism explaining how the disordered adrenal development and function 
is caused remains unknown for many of them. In the following we will 
discuss a couple of syndromes that have been genetically solved only 
recently. 
The IMAGe syndrome comprises Intrauterine growth retardation, 
Metaphyseal dysplasia, Adrenal hypoplasia, and Genitourinary anoma-
lies (Vilain et al., 1999). Linkage analysis in affected patients and their 
families identified dominant missense mutations in the specific prolif-
erating cell nuclear antigen (PCNA) domain of the cyclin-dependent ki-
nase inhibitor 1C (CDKN1C) gene (Arboleda et al., 2012). The CDKN1C 
gene encodes p57KIP2, which inhibits several cyclin-dependent kinases. 
This gene lies in the imprinted region of chromosome 11p15.5. Only the 
maternal allele is expressed. Interestingly, different variants in this gene 
cause Beckwith-Wiedemann overgrowth syndrome (Hatada et al., 
1996). By contrast to gain-of-function mutations causing IMAGe syn-
drome, loss-of-function Beckwith mutations inhibit the cell cycle. 
IMAGe mutations typically cause restricted growth (Arboleda et al., 
2012). Thus variants in the same gene cause both the IMAGe adrenal 
hypoplasia syndrome with IUGR and the Beckwith-Wiedemann adrenal 
hyperplasia overgrowth syndrome (Eggermann et al., 2014). Interest-
ingly, biallelic mutations in POLE1 also cause IMAGe syndrome (Logan 
et al., 2018). POLε is one of the leading polymerases for DNA replication 
essential for transmission of genetic information. All CDKN1C mutations 
identified in IMAGE syndrome cluster in the PCNA binding domain. At 
replication initiation PCNA loads with POLε providing a mechanistic 
link between CDKN1C and POLE1. 
MIRAGE syndrome is characterized by Myelodysplasia, Infections, 
Restricted growth, Adrenal hypoplasia, Genital anomalies, Enteropathy 
and early death (Narumi et al., 2016). Affected individuals have het-
erozygous mutations of the SAMD9 gene on chromosome 7q. These 
mutations cause gain-of-function of the growth repressor SAMD9. 
SAMD9 is involved in endosome fusion and plays a role in growth factor 
signaling transduction. Heterozygous SAMD9 mutations enhance its 
endosome-fusing activity and may thereby lead to abnormal tissue 
development including dysgenetic and hypoplastic adrenal glands, 
ovaries and thymus, and result in overall growth restriction and short 
survival. In some patients progressive loss of mutated SAMD9 by somatic 
adaptive changes in the bone marrow leading to monosomy 7 rescued 
the negative effect on growth and survival, but increased their risk for 
myelodysplastic syndromes (Buonocore et al., 2017). 
Recessive loss-of-function mutations in the gene for sphingosine-1- 
phosphate (S1P) lyase 1 (SGPL1) cause syndromic PAI associated with 
steroid-resistant nephrotic syndrome, variably accompanied by ich-
thyosis, primary hypothyroidism, cryptorchidism, immunodeficiency 
and neurological anomalies (Janecke et al., 2017; Lovric et al., 2017; 
Prasad et al., 2017). SGPL1 enzyme catalyzes the final breakdown of 
sphingolipid S1P. S1P regulates cell migration, differentiation, survival 
as well as angiogenesis and development. However, the pathogenesis of 
SGPL1 deficiency within a target organ remains unknown (Lovric et al., 
2017). The pathogenesis of PAI in SGPL1 deficiency includes both 
compromised adrenal development as well as disrupted steroidogenesis 
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(Prasad et al., 2017). Adrenals of Sgpl1 null mice revealed marked al-
terations in adrenocortical zonation, while CYP11A1 expression was 
significantly decreased. They die within a few weeks and show impaired 
gonadal steroidogenesis and reproduction (Prasad et al., 2017). 
5. Adrenal research models and their opportunities and 
challenges 
5.1. Human disorders 
Human disorders are experiments of nature that offer unique op-
portunities to better understand biology. Through comprehensive phe-
notyping and genotyping many diseases have been solved to the 
molecular level and hinted pathophysiology amenable for diagnostic 
and therapeutic opportunities. Recent advances in next generation 
sequencing (NGS) using an unbiased approach revealed a genetic diag-
nosis for many disorders in genes that were not suspected previously. 
This is clearly also the case for disorders of the adrenal cortex. Currently, 
NGS approaches are able to find a plausible genetic cause in 60–80% of 
individuals with PAI (Amano et al., 2017; Guran, 2017). However, NGS 
creates big data with numerous genetic variants of unknown signifi-
cance for each individual tested. In addition to bioinformatic tools for 
analyzing such data, novel gene variants should be tested for their dis-
ease causing effect by functional studies and validated in other affected 
persons (Richards et al., 2015). For these studies several models may be 
employed. 
5.2. Mouse models 
The use of animal models for the study of adrenal physiology is often 
limited due to significant species-specific differences in fetal adrenal 
structure, steroidogenic pathways and endocrinology of pregnancy 
(Basham et al., 2016; Ratajczak et al., 2010; Ruiz-Babot et al., 2018). 
Therefore, different human disorders are recapitulated by a specific 
animal model to variable extent. For instance, inactivation of both al-
leles of WNT4 results in the SERKAL syndrome, which presents with a 
high mortality rate during fetal life with associated lung, kidney and 
adrenal dysgenesis; likewise, mice homozygous for Wnt4 exhibit peri-
natal lethality with a similar phenotype. In contrast, while Tcf21 dele-
tion in mice leads to hypoplasia of lungs, kidneys and vasculature, in 
human this gene is not linked to any disease. On the other hand, the 
AAAS gene is linked to the AAA syndrome in human, but there is no 
adrenal phenotype in the mouse (see Tables 1 and 2). All these results 
indicate that researchers and caregivers must use caution when inter-
preting evidence obtained in other species. 
Still, gene inactivation and overactivation studies, together with 
hormonal manipulation in mouse models have been instrumental to 
understand key mechanisms in adrenal functional zonation and adult 
homeostasis. In particular, the past 15 years of adrenal research on 
mouse models have unveiled the identity and stemness potential of 
adrenal progenitor cells, opening new venues for understanding the 
mechanisms of cell differentiation and translating these mechanisms for 
in vitro differentiation of adrenocortical cells (Hammer and Basham, 
2021). Results from recent studies on mouse models have started to 
reveal sex dimorphic aspects of adrenal homeostatic maintenance and 
regeneration, which have the potential to shed light on the sex bias that 
characterizes many adrenal disorders (Dumontet et al., 2018; El Wakil 
et al., 2013; Grabek et al., 2019). 
5.3. Cells models and organoids 
In the past, mechanistic studies of steroidogenesis have predomi-
nantly relied on immortalized cell systems (Rainey et al., 2004). Lately, 
it has been shown that human fetal adrenal cells retain age-, stem- and 
endocrine characteristics when grown as organoids in culture (Poli et al., 
2019). Such organoids bear the potential to better assist in studies of 
normal adrenal gland development as well as in studies of the patho-
physiology of adrenal hyper- and hypoplasia. In addition, human 
derived (pluripotent stem) cell models help for mechanistic or diag-
nostic studies and bear the potential to be developed into personalized 
cell-based therapeutics. Using this approach, patient derived mesen-
chymal cells from urine were recently developed into human induced 
steroidogenic cells (hiSCs) by expression of SF-1 and activation of the 
PKA and LHRH pathways (Ruiz-Babot et al., 2018). Remarkably, 
hypocortisolism of hiSCs originating from CAH patients could be 
rescued by overexpression of the wild-type gene of the disease-causing 
enzyme. 
6. Conclusion and perspectives 
Failure of adrenal function is not compatible with survival. Treat-
ment of all forms of adrenal insufficiency consists of replacement of 
steroid hormones, e.g. mineralocorticoids and glucocorticoids as soon as 
the diagnosis is made. This can prevent life-threatening adrenal crisis. 
Sex hormone replacement may be added, if gonadal steroidogenesis is 
affected. Adrenal androgen excess as a consequence of negative feed-
back overstimulation through the HPA axis in CAH mainly due to 
CYP21A2 is often difficult to control with corticosteroid replacement 
only and may therefore require additional anti-androgenic treatments, 
especially in females. Thus, there is an unmet need for improved ther-
apy. Better treatment or even a cure for some monogenic forms of PAI 
may be achieved in the near future through gene therapeutic options. 
For that comprehensive studies for understanding adrenal cortex 
development and function in health and disease are fundamental. 
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Heikkilä, M., Peltoketo, H., Leppäluoto, J., Ilves, M., Vuolteenaho, O., Vainio, S., 2002. 
Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone 
production. Endocrinology 143, 4358–4365. https://doi.org/10.1210/en.2002- 
220275. 
Heitzmann, D., Derand, R., Jungbauer, S., Bandulik, S., Sterner, C., Schweda, F., El 
Wakil, A., Lalli, E., Guy, N., Mengual, R., Reichold, M., Tegtmeier, I., Bendahhou, S., 
Gomez-Sanchez, C.E., Aller, M.I., Wisden, W., Weber, A., Lesage, F., Warth, R., 
Barhanin, J., 2008. Invalidation of TASK1 potassium channels disrupts adrenal gland 
zonation and mineralocorticoid homeostasis. EMBO J. 27, 179–187. https://doi.org/ 
10.1038/sj.emboj.7601934. 
Hohenstein, P., Hastie, N.D., 2006. The many facets of the Wilms’ tumour gene, WT1. 
Hum. Mol. Genet. 15 (2), R196–R201. https://doi.org/10.1093/hmg/ddl196. 
Huang, C.-C.J., Miyagawa, S., Matsumaru, D., Parker, K.L., Yao, H.H.-C., 2010. 
Progenitor cell expansion and organ size of mouse adrenal is regulated by sonic 
hedgehog. Endocrinology 151, 1119–1128. https://doi.org/10.1210/en.2009-0814. 
Huebner, A., Mann, P., Rohde, E., Kaindl, A.M., Witt, M., Verkade, P., Jakubiczka, S., 
Menschikowski, M., Stoltenburg-Didinger, G., Koehler, K., 2006. Mice lacking the 
nuclear pore complex protein ALADIN show female infertility but fail to develop a 
phenotype resembling human triple A syndrome. Mol. Cell Biol. 26, 1879–1887. 
https://doi.org/10.1128/MCB.26.5.1879-1887.2006. 
Huebner, A., Yoon, S.J., Ozkinay, F., Hilscher, C., Lee, H., Clark, A.J., Handschug, K., 
2000. Triple A syndrome–clinical aspects and molecular genetics. Endocr. Res. 26, 
751–759. https://doi.org/10.3109/07435800009048596. 
Hughes, C.R., Guasti, L., Meimaridou, E., Chuang, C.H., Schimenti, J.C., King, P.J., 
Costigan, C., Clark, A.J., Metherell, L.A., 2012. MCM4 mutation causes adrenal 
failure, short stature, and natural killer cell deficiency in humans. J. Clin. Invest. 
122, 814–820. https://doi.org/10.1172/JCI60224. 
Hummel, S.R., Sadler, S., Whitaker, M.J., Ara, R.M., Dixon, S., Ross, R.J., 2016. A model 
for measuring the health burden of classic congenital adrenal hyperplasia in adults. 
Clin. Endocrinol. 85, 361–398. https://doi.org/10.1111/cen.13060. 
Ishimoto, H., Jaffe, R.B., 2011. Development and function of the human fetal adrenal 
cortex: a key component in the feto-placental unit. Endocr. Rev. 32, 317–355. 
https://doi.org/10.1210/er.2010-0001. 
Janecke, A.R., Xu, R., Steichen-Gersdorf, E., Waldegger, S., Entenmann, A., Giner, T., 
Krainer, I., Huber, L.A., Hess, M.W., Frishberg, Y., Barash, H., Tzur, S., Schreyer- 
Shafir, N., Sukenik-Halevy, R., Zehavi, T., Raas-Rothschild, A., Mao, C., Muller, T., 
2017. Deficiency of the sphingosine-1-phosphate lyase SGPL1 is associated with 
congenital nephrotic syndrome and congenital adrenal calcifications. Hum. Mutat. 
38, 365–372. https://doi.org/10.1002/humu.23192. 
Johnston, Z.C., Bellingham, M., Filis, P., Soffientini, U., Hough, D., Bhattacharya, S., 
Simard, M., Hammond, G.L., King, P., O’Shaughnessy, P.J., Fowler, P.A., 2018. The 
human fetal adrenal produces cortisol but no detectable aldosterone throughout the 
second trimester. BMC Med. 16, 23. https://doi.org/10.1186/s12916-018-1009-7. 
Kadmiel, M., Cidlowski, J.A., 2013. Glucocorticoid receptor signaling in health and 
disease. Trends Pharmacol. Sci. 34, 518–530. https://doi.org/10.1016/j. 
tips.2013.07.003. 
Kamrath, C., Hartmann, M.F., Wudy, S.A., 2013. Androgen synthesis in patients with 
congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormone and 
metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
metabolisme 45, 86–91. https://doi.org/10.1055/s-0032-1331751. 
Kamrath, C., Wettstaedt, L., Boettcher, C., Hartmann, M.F., Wudy, S.A., 2018. Androgen 
excess is due to elevated 11-oxygenated androgens in treated children with 
congenital adrenal hyperplasia. J. Steroid Biochem. Mol. Biol. 178, 221–228. 
https://doi.org/10.1016/j.jsbmb.2017.12.016. 
Kim, A.C., Reuter, A.L., Zubair, M., Else, T., Serecky, K., Bingham, N.C., Lavery, G.G., 
Parker, K.L., Hammer, G.D., 2008. Targeted disruption of beta-catenin in Sf1- 
expressing cells impairs development and maintenance of the adrenal cortex. 
Development 135, 2593–2602. https://doi.org/10.1242/dev.021493. 
Kim, S.K., Selleri, L., Lee, J.S., Zhang, A.Y., Gu, X., Jacobs, Y., Cleary, M.L., 2002. Pbx1 
inactivation disrupts pancreas development and in Ipf1-deficient mice promotes 
diabetes mellitus. Nat. Genet. 30, 430–435. https://doi.org/10.1038/ng860. 
King, P., Paul, A., Laufer, E., 2009. Shh signaling regulates adrenocortical development 
and identifies progenitors of steroidogenic lineages. Proc. Natl. Acad. Sci. Unit. 
States Am. 106, 21185–21190. https://doi.org/10.1073/pnas.0909471106. 
Koutsourakis, M., Langeveld, A., Patient, R., Beddington, R., Grosveld, F., 1999. The 
transcription factor GATA6 is essential for early extraembryonic development. 
Development 126, 723–732. 
Kranc, K.R., Schepers, H., Rodrigues, N.P., Bamforth, S., Villadsen, E., Ferry, H., Bouriez- 
Jones, T., Sigvardsson, M., Bhattacharya, S., Jacobsen, S.E., Enver, T., 2009. Cited2 
is an essential regulator of adult hematopoietic stem cells. Cell Stem Cell 5, 659–665. 
https://doi.org/10.1016/j.stem.2009.11.001. 
Kreidberg, J.A., Sariola, H., Loring, J.M., Maeda, M., Pelletier, J., Housman, D., 
Jaenisch, R., 1993. WT-1 is required for early kidney development. Cell 74, 
679–691. https://doi.org/10.1016/0092-8674(93)90515-r. 
Kyrönlahti, A., Euler, R., Bielinska, M., Schoeller, E.L., Moley, K.H., Toppari, J., 
Heikinheimo, M., Wilson, D.B., 2011a. GATA4 regulates Sertoli cell function and 
fertility in adult male mice. Mol. Cell. Endocrinol. 333, 85–95. https://doi.org/ 
10.1016/j.mce.2010.12.019. 
Kyrönlahti, A., Vetter, M., Euler, R., Bielinska, M., Jay, P.Y., Anttonen, M., 
Heikinheimo, M., Wilson, D.B., 2011b. GATA4 deficiency impairs ovarian function 
in adult mice. Biol. Reprod. 84, 1033–1044. https://doi.org/10.1095/ 
biolreprod.110.086850. 
Lalli, E., Sassone-Corsi, P., 2003. DAX-1, an unusual orphan receptor at the crossroads of 
steroidogenic function and sexual differentiation. Mol. Endocrinol. 17, 1445–1453. 
https://doi.org/10.1210/me.2003-0159. 
Lamers, W.H., Mooren, P.G., Griep, H., Endert, E., Degenhart, H.J., Charles, R., 1986. 
Hormones in perinatal rat and spiny mouse: relation to altricial and precocial timing 
of birth. Am. J. Physiol. 251, E78–E85. https://doi.org/10.1152/ 
ajpendo.1986.251.1.E78. 
Lehmann, S.G., Lalli, E., Sassone-Corsi, P., 2002. X-linked adrenal hypoplasia congenita 
is caused by abnormal nuclear localization of the DAX-1 protein. Proc. Natl. Acad. 
Sci. U. S. A. 99, 8225–8230. https://doi.org/10.1073/pnas.122044099. 
Leng, S., Pignatti, E., Khetani, R.S., Shah, M.S., Xu, S., Miao, J., Taketo, M.M., 
Beuschlein, F., Barrett, P.Q., Carlone, D.L., Breault, D.T., 2020. β-Catenin and FGFR2 
regulate postnatal rosette-based adrenocortical morphogenesis. Nat. Commun. 11, 
1680. https://doi.org/10.1038/s41467-020-15332-7. 
Lever, J.D., 1952. Observations on the adrenal blood vessels in the rat. J. Anat. 86, 
459–467. 
Li, J., Lu, Y., Liu, R., Xiong, X., Zhang, Z., Zhang, X., Ning, G., Li, X., 2011. DAX1 
suppresses FXR transactivity as a novel co-repressor. Biochem. Biophys. Res. 
Commun. 412, 660–666. https://doi.org/10.1016/j.bbrc.2011.08.020. 
Logan, C.V., Murray, J.E., Parry, D.A., Robertson, A., Bellelli, R., Tarnauskaite, Z., 
Challis, R., Cleal, L., Borel, V., Fluteau, A., Santoyo-Lopez, J., Aitman, T., Barroso, I., 
Basel, D., Bicknell, L.S., Goel, H., Hu, H., Huff, C., Hutchison, M., Joyce, C., Knox, R., 
Lacroix, A.E., Langlois, S., McCandless, S., McCarrier, J., Metcalfe, K.A., 
Morrissey, R., Murphy, N., Netchine, I., O’Connell, S.M., Olney, A.H., Paria, N., 
Rosenfeld, J.A., Sherlock, M., Syverson, E., White, P.C., Wise, C., Yu, Y., 
Zacharin, M., Banerjee, I., Reijns, M., Bober, M.B., Semple, R.K., Boulton, S.J., 
Rios, J.J., Jackson, A.P., 2018. DNA polymerase epsilon deficiency causes IMAGe 
syndrome with variable immunodeficiency. Am. J. Hum. Genet. 103, 1038–1044. 
https://doi.org/10.1016/j.ajhg.2018.10.024. 
Lovric, S., Goncalves, S., Gee, H.Y., Oskouian, B., Srinivas, H., Choi, W.I., Shril, S., 
Ashraf, S., Tan, W., Rao, J., Airik, M., Schapiro, D., Braun, D.A., Sadowski, C.E., 
Widmeier, E., Jobst-Schwan, T., Schmidt, J.M., Girik, V., Capitani, G., Suh, J.H., 
Lachaussee, N., Arrondel, C., Patat, J., Gribouval, O., Furlano, M., Boyer, O., 
Schmitt, A., Vuiblet, V., Hashmi, S., Wilcken, R., Bernier, F.P., Innes, A.M., 
E. Pignatti and C.E. Flück                                                                                                                                                                                                                     
Molecular and Cellular Endocrinology 527 (2021) 111206
16
Parboosingh, J.S., Lamont, R.E., Midgley, J.P., Wright, N., Majewski, J., Zenker, M., 
Schaefer, F., Kuss, N., Greil, J., Giese, T., Schwarz, K., Catheline, V., Schanze, D., 
Franke, I., Sznajer, Y., Truant, A.S., Adams, B., Desir, J., Biemann, R., Pei, Y., Ars, E., 
Lloberas, N., Madrid, A., Dharnidharka, V.R., Connolly, A.M., Willing, M.C., 
Cooper, M.A., Lifton, R.P., Simons, M., Riezman, H., Antignac, C., Saba, J.D., 
Hildebrandt, F., 2017. Mutations in sphingosine-1-phosphase lyase cause nephrosis 
with ichthyosis and adrenal insufficiency. J. Clin. Invest. https://doi.org/10.1172/ 
JCI89626. 
Lu, J., Chang, P., Richardson, J.A., Gan, L., Weiler, H., Olson, E.N., 2000. The basic helix- 
loop-helix transcription factor capsulin controls spleen organogenesis. Proc. Natl. 
Acad. Sci. U. S. A. 97, 9525–9530. https://doi.org/10.1073/pnas.97.17.9525. 
Lumb, R., Schwarz, Q., 2015. Sympathoadrenal neural crest cells: the known, unknown 
and forgotten? Development. Growth & Differentiation 57, 146–157. https://doi. 
org/10.1111/dgd.12189. 
Luo, X., Ikeda, Y., Parker, K.L., 1994. A cell-specific nuclear receptor is essential for 
adrenal and gonadal development and sexual differentiation. Cell 77, 481–490. 
Maharaj, A., Maudhoo, A., Chan, L.F., Novoselova, T., Prasad, R., Metherell, L.A., 
Guasti, L., 2019. Isolated glucocorticoid deficiency: genetic causes and animal 
models. J. Steroid Biochem. Mol. Biol. 189, 73–80. https://doi.org/10.1016/j. 
jsbmb.2019.02.012. 
Makhanova, N., Sequeira-Lopez, M.L.S., Gomez, R.A., Kim, H.-S., Smithies, O., 2006. 
Disturbed homeostasis in sodium-restricted mice heterozygous and homozygous for 
aldosterone synthase gene disruption. Hypertension 48, 1151–1159. https://doi.org/ 
10.1161/01.HYP.0000249902.09036.e7. 
Mandel, H., Shemer, R., Borochowitz, Z.U., Okopnik, M., Knopf, C., Indelman, M., 
Drugan, A., Tiosano, D., Gershoni-Baruch, R., Choder, M., Sprecher, E., 2008. 
SERKAL syndrome: an autosomal-recessive disorder caused by a loss-of-function 
mutation in WNT4. Am. J. Hum. Genet. 82, 39–47. https://doi.org/10.1016/j. 
ajhg.2007.08.005. 
Mantovani, G., De Menis, E., Borretta, G., Radetti, G., Bondioni, S., Spada, A., Persani, L., 
Beck-Peccoz, P., 2006. DAX1 and X-linked adrenal hypoplasia congenita: clinical and 
molecular analysis in five patients. Eur. J. Endocrinol. 154, 685–689. https://doi. 
org/10.1530/eje.1.02132. 
Mathieu, M., Drelon, C., Rodriguez, S., Tabbal, H., Septier, A., Damon-Soubeyrand, C., 
Dumontet, T., Berthon, A., Sahut-Barnola, I., Djari, C., Batisse-Lignier, M., 
Pointud, J.-C., Richard, D., Kerdivel, G., Calméjane, M.-A., Boeva, V., Tauveron, I., 
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